<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAH</journal-id>
<journal-id journal-id-type="hwp">sptah</journal-id>
<journal-title>Therapeutic Advances in Hematology</journal-title>
<issn pub-type="ppub">2040-6207</issn>
<issn pub-type="epub">2040-6215</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2040620713498161</article-id>
<article-id pub-id-type="publisher-id">10.1177_2040620713498161</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Genetic predispositions to childhood leukemia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Stieglitz</surname><given-names>Elliot</given-names></name>
<aff id="aff1-2040620713498161">Department of Pediatrics, Benioff Children’s Hospital, University of California San Francisco, USA</aff>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Loh</surname><given-names>Mignon L.</given-names></name>
<aff id="aff2-2040620713498161">Department of Pediatrics, Benioff Children’s Hospital, 513 Parnassus Ave, HSE-302, Box 0519, University of California San Francisco/ Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94143, USA</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-2040620713498161"><email>lohm@peds.ucsf.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>4</volume>
<issue>4</issue>
<fpage>270</fpage>
<lpage>290</lpage>
<permissions>
<copyright-statement>© The Author(s), 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>While the majority of leukemia cases occur in the absence of any known predisposing factor, there are germline mutations that significantly increase the risk of developing hematopoietic malignancies in childhood. In this review article, we describe a number of these mutations and their clinical features. These predispositions can be broadly classified as those leading to bone marrow failure, those involving tumor suppressor genes, DNA repair defects, immunodeficiencies or other congenital syndromes associated with transient myeloid disorders. While leukemia can develop as a secondary event in the aforementioned syndromes, there are also several syndromes that specifically lead to the development of leukemia as their primary phenotype. Many of the genes discussed in this review can also be somatically mutated in other cancers, highlighting the importance of understanding shared alterations and mechanisms underpinning syndromic and sporadic leukemia.</p>
</abstract>
<kwd-group>
<kwd>genetic predisposition</kwd>
<kwd>germline</kwd>
<kwd>hematologic malignancy</kwd>
<kwd>leukemia</kwd>
<kwd>oncogene</kwd>
<kwd>cancer syndrome</kwd>
<kwd>tumor suppressor</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-2040620713498161" sec-type="intro">
<title>Introduction</title>
<p>The risk of developing childhood leukemia is significantly increased in the setting of germline genetic mutations, which can either be inherited or occur <italic>de novo</italic> in the patient’s germline. This review focuses on describing the molecular basis of multiple germline syndromes that confer an increased risk of leukemia, and will specifically highlight several genes that appear to increase this risk in the absence of other significant clinical manifestations (<xref ref-type="table" rid="table1-2040620713498161">Table 1</xref>). These discoveries have led to improved surveillance guidelines for affected children and their families, and have also facilitated a deeper understanding of the normal function of these mutated genes. A number of genes discussed in this paper are also somatically mutated in other human cancers and thus further understanding of the biochemical consequences of these lesions can shed light on disease pathogenesis and the identification of novel therapeutic targets in syndromic and nonsyndromic cancer alike.</p>
<table-wrap id="table1-2040620713498161" position="float">
<label>Table 1.</label>
<caption><p>Inherited predispositions to childhood hematologic malignancy.</p></caption>
<graphic alternate-form-of="table1-2040620713498161" xlink:href="10.1177_2040620713498161-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Gene</th>
<th align="left">Locus</th>
<th align="left">Inheritance</th>
<th align="left">Type of leukemia</th>
<th align="left">Incidence of leukemia</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6"><bold>Pure familial leukemia</bold></td>
</tr>
<tr>
<td><italic>CEBPA</italic></td>
<td><italic>CEBPA</italic></td>
<td>19q13.1</td>
<td>AD</td>
<td>MDS/AML</td>
<td>Unknown</td>
</tr>
<tr>
<td>Familial platelet disorder/AML</td>
<td><italic>RUNX1</italic></td>
<td>21q22.12</td>
<td>AD</td>
<td>MDS/AML</td>
<td>35%</td>
</tr>
<tr>
<td>MonoMAC syndrome</td>
<td><italic>GATA2</italic></td>
<td>3q21.3</td>
<td>AD</td>
<td>MDS/AML</td>
<td>Unknown</td>
</tr>
<tr>
<td>Monosomy 7</td>
<td>Unknown</td>
<td>7p/q</td>
<td>AD</td>
<td>ALL, MDS/AML</td>
<td>Unknown</td>
</tr>
<tr>
<td colspan="6"><bold>Bone marrow failure syndromes</bold></td>
</tr>
<tr>
<td>Diamond Blackfan anemia</td>
<td><italic>RPS19, RPL5, RPL11</italic></td>
<td>19q13.2, 1p22.1, 1p35</td>
<td>Sporadic, AD, AR</td>
<td>MDS/AML, ALL</td>
<td>2%</td>
</tr>
<tr>
<td>Shwachman–Diamond syndrome</td>
<td><italic>SBDS</italic></td>
<td>7q11.21</td>
<td>AR</td>
<td>MDS/AML, ALL</td>
<td>19–36%</td>
</tr>
<tr>
<td>Amegakaryocytic thrombocytopenia</td>
<td><italic>c-MPL</italic></td>
<td>1p34.2</td>
<td>AR</td>
<td>MDS/AML</td>
<td>2%</td>
</tr>
<tr>
<td>Thrombocytopenia and absent radii syndrome</td>
<td><italic>RBM8A</italic></td>
<td>1q21.1</td>
<td>AR, Sporadic</td>
<td>AML, ALL</td>
<td>1%</td>
</tr>
<tr>
<td>Dyskeratosis congenita</td>
<td><italic>DKC1, TIN2, TERC, TERT, NOP10</italic></td>
<td>Xq28, 14q11, 3q26.2, 5p15, 15q14</td>
<td>X-linked, AD, AR</td>
<td>MDS/AML</td>
<td>2%</td>
</tr>
<tr>
<td>Severe congenital neutropenia</td>
<td><italic>ELA2, HAX1, G6PC3, WASP</italic></td>
<td>19p13, 1q21.3 17q21, Xp11</td>
<td>AD, AR, X-linked</td>
<td>MDS/AML</td>
<td>10%</td>
</tr>
<tr>
<td colspan="6"><bold>Tumor suppressor gene syndromes</bold></td>
</tr>
<tr>
<td>Li-Fraumeni syndrome</td>
<td><italic>TP53</italic></td>
<td>17p13.1</td>
<td>AD</td>
<td>ALL</td>
<td>2–4%</td>
</tr>
<tr>
<td>Neurofibromatosis type 1</td>
<td><italic>NF1</italic></td>
<td>17q11.2</td>
<td>AD</td>
<td>JMML, MDS/AML</td>
<td>Unknown</td>
</tr>
<tr>
<td>Noonan syndrome</td>
<td><italic>PTPN11</italic></td>
<td>12q24.13</td>
<td>AD</td>
<td>TMD, JMML, CMML</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>CBL syndrome</td>
<td><italic>CBL</italic></td>
<td>11q23.3</td>
<td>AD</td>
<td>JMML</td>
<td>&lt;1%</td>
</tr>
<tr>
<td colspan="6"><bold>DNA repair gene syndromes</bold></td>
</tr>
<tr>
<td>Mismatch repair cancer syndrome</td>
<td><italic>PMS2, MSH6, MLH1, MSH2</italic></td>
<td>7p22.2, 2p16, 3p22.2, 2p21</td>
<td>AR</td>
<td>ALL</td>
<td>Unknown</td>
</tr>
<tr>
<td>Fanconi anemia</td>
<td><italic>FANC A-E, BRCA</italic></td>
<td>16q24.3, 9q22</td>
<td>AR</td>
<td>ALL, AML</td>
<td>10%</td>
</tr>
<tr>
<td>Ataxia telangiectasia</td>
<td><italic>ATM</italic></td>
<td>11q22.3</td>
<td>AR</td>
<td>ALL</td>
<td>Unknown</td>
</tr>
<tr>
<td>Nijmegen breakage syndrome</td>
<td><italic>NBS1</italic></td>
<td>8q21.3</td>
<td>AR</td>
<td>ALL</td>
<td>50%</td>
</tr>
<tr>
<td>Bloom syndrome</td>
<td><italic>BLM</italic></td>
<td>15q26.1</td>
<td>AR</td>
<td>ALL</td>
<td>12%</td>
</tr>
<tr>
<td>Werner syndrome</td>
<td><italic>WRN (RECQL2)</italic></td>
<td>8p12</td>
<td>AR</td>
<td>MDS/AML</td>
<td>Unknown</td>
</tr>
<tr>
<td>Rothmund–Thomson</td>
<td><italic>RECQL4</italic></td>
<td>8q24.3</td>
<td>AR</td>
<td>AML</td>
<td>Unknown</td>
</tr>
<tr>
<td colspan="6"><bold>Immunodeficiency syndromes</bold></td>
</tr>
<tr>
<td>Wiskott–Aldrich syndrome</td>
<td><italic>WASP</italic></td>
<td>Xp11.23</td>
<td>X-linked</td>
<td>ALL</td>
<td>13%</td>
</tr>
<tr>
<td>Bruton’s agammaglobulinemia</td>
<td><italic>BTK</italic></td>
<td>Xq22.1</td>
<td>X-linked</td>
<td>ALL</td>
<td>Unknown</td>
</tr>
<tr>
<td colspan="6"><bold>Down syndrome</bold></td>
</tr>
<tr>
<td>Trisomy 21</td>
<td>Unknown</td>
<td>21q</td>
<td>Sporadic</td>
<td>TMD, ALL, AML</td>
<td>10% for TMD, 1–2% for ALL/AML</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-2040620713498161">
<p>The most frequent mutations for each syndrome are listed here. When multiple items are reported in one field, they are listed in order of decreasing frequency.</p>
<p>AD, autosomal dominant; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; AR, autosomal recessive; CMML, chronic myelomonocytic leukemia; JMML, juvenile myelomonocytic leukemia; MDS, myelodysplastic syndrome; TMD, transient myeloproliferative disorder.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section2-2040620713498161">
<title>Familial leukemia</title>
<p>While it is well known that patients with bone marrow failure disorders, DNA repair defects, and constitutional chromosomal anomalies are predisposed to developing hematologic malignancies, a more recent discovery reveals that there are inherited mutations that innately increase the risk of developing leukemia in the absence of extramedullary phenotypes [<xref ref-type="bibr" rid="bibr112-2040620713498161">Owen <italic>et al.</italic> 2007</xref>]. Some have coined these inherited malignancies as ‘pure familial leukemia’ to differentiate them from leukemias that arise in the context of other comorbidities [<xref ref-type="bibr" rid="bibr66-2040620713498161">Horwitz, 1997</xref>]. However, it should be noted that other cytopenias such as neutropenia and thrombocytopenia can be seen without concomitant leukemia in these disorders, thereby displaying other hematologic manifestations. While there have been many case reports detailing family pedigrees with an increased incidence of leukemia in the absence of a known inherited mutation [<xref ref-type="bibr" rid="bibr56-2040620713498161">Goldgar <italic>et al.</italic> 1994</xref>; <xref ref-type="bibr" rid="bibr60-2040620713498161">Gunz <italic>et al.</italic> 2009</xref>], to date there have been three genes identified that can be inherited in an autosomal dominant fashion and specifically predispose people to the development of leukemia: <italic>CEPBA, RUNX1</italic>, and <italic>GATA2</italic>. In this section we also discuss familial inheritance of monosomy 7 and its unique association with predisposing individuals to leukemia.</p>
<sec id="section3-2040620713498161">
<title>CEBPA</title>
<p><italic>CEBPA</italic> resides at 19q13.1 and encodes the granulocytic differentiation factor C/EBPα, which belongs to the bZIP family of proteins and plays a role in myeloid differentiation [<xref ref-type="bibr" rid="bibr115-2040620713498161">Pabst <italic>et al.</italic> 2001</xref>]. While somatic mutations and rearrangements in this gene occur in acute myeloid leukemia (AML) and confer a favorable outcome [<xref ref-type="bibr" rid="bibr123-2040620713498161">Preudhomme, 2002</xref>], germline mutations of <italic>CEBPA</italic> were identified in 2004 [<xref ref-type="bibr" rid="bibr149-2040620713498161">Smith <italic>et al.</italic> 2004</xref>]. After developing AML with a latency period ranging from 10 to 30 years after birth, a father and two children were found to be heterozygous germline carriers of a <italic>CEBPA</italic>-mutant allele resulting in a frame shift deletion. Interestingly, only one of the three affected family members developed a mutation in the residual wild-type allele of their leukemic cells. A more recent analysis has shown that additional but distinct somatic mutations in <italic>CEBPA</italic> occasionally occur in patients who inherit germline mutations of the same gene and likely contribute to the development of AML [<xref ref-type="bibr" rid="bibr114-2040620713498161">Pabst <italic>et al.</italic> 2008</xref>]. Since the first report in 2004, there have been several additional reported pedigrees that document that germline transmission of <italic>CEBPA</italic> mutations leads to familial AML [<xref ref-type="bibr" rid="bibr143-2040620713498161">Sellick <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr129-2040620713498161">Renneville <italic>et al.</italic> 2008</xref>].</p>
</sec>
<sec id="section4-2040620713498161">
<title>RUNX1 familial platelet disorder/acute myeloid leukemia</title>
<p>The underlying genetic defects in the autosomal dominant familial platelet disorder with a propensity to myeloid malignancy (FPD/AML) are mutations in the <italic>RUNX1</italic> gene located at 21q22.12 [<xref ref-type="bibr" rid="bibr150-2040620713498161">Song <italic>et al.</italic> 1999</xref>]. <italic>RUNX1</italic> is a transcription factor broadly involved in hematopoiesis, and mutations and/or translocations involving the gene have been reported in acute lymphoblastic leukemia (ALL), AML and myelodysplastic syndrome (MDS) [<xref ref-type="bibr" rid="bibr98-2040620713498161">McLean <italic>et al.</italic> 1996</xref>; <xref ref-type="bibr" rid="bibr48-2040620713498161">Gaidzik <italic>et al.</italic> 2011</xref>]. The most common somatic abnormality involving the <italic>RUNX1</italic> gene in sporadic AML or ALL is usually a translocation. However, in MDS or FPD/AML associated with <italic>RUNX1</italic> alterations, the most common type of mutation is a point mutation resulting in haploinsufficiency [<xref ref-type="bibr" rid="bibr150-2040620713498161">Song <italic>et al.</italic> 1999</xref>; <xref ref-type="bibr" rid="bibr110-2040620713498161">Osato, 2004</xref>]. Recently, deletions due to nonallelic homologous recombination have been reported, highlighting the importance of using screening methodologies to detect sequence variation and copy number alterations [<xref ref-type="bibr" rid="bibr70-2040620713498161">Jongmans <italic>et al.</italic> 2009</xref>]. The incidence of progression to MDS/AML is approximately 35% [<xref ref-type="bibr" rid="bibr113-2040620713498161">Owen <italic>et al.</italic> 2008</xref>]. There have been 19 families to date with documented germline mutations in <italic>RUNX1</italic>, although the low prevalence may be related to the lack of awareness regarding this inherited syndrome. In addition, variable expressivity leading to a range of thrombocytopenia and varied latency for the development of MDS/AML (7–68 years of age at diagnosis) make this condition difficult to identify. However, since treatment of childhood MDS and AML frequently involves hematopoietic stem cell transplant, careful attention should be paid to the family history, as screening potential donor siblings for the same mutation is necessary. Indeed, the development of AML in the donor cells of previously asymptomatic siblings after transplant has been documented [<xref ref-type="bibr" rid="bibr113-2040620713498161">Owen <italic>et al.</italic> 2008</xref>].</p>
</sec>
<sec id="section5-2040620713498161">
<title>GATA2 MonoMAC syndrome</title>
<p>MonoMAC syndrome was first identified in 2010 as an immunodeficiency characterized by nontuberculosis mycobacterial infection, opportunistic fungal infections, human papilloma virus (HPV) infections, and monocytopenia with an increased incidence of MDS/AML [<xref ref-type="bibr" rid="bibr167-2040620713498161">Vinh <italic>et al.</italic> 2010</xref>]. Simultaneously, Hahn and colleagues reported four families displaying an autosomal dominant inheritance pattern with predisposition to MDS/AML that resulted from mutations in the <italic>GATA2</italic> gene found on 3q21.3 [<xref ref-type="bibr" rid="bibr62-2040620713498161">Hahn <italic>et al.</italic> 2011</xref>]. Based on the overlapping features in these two reports, Hsu and colleagues screened 13 kindreds with MonoMAC syndrome and identified a germline <italic>GATA2</italic> mutation in 10 pedigrees [<xref ref-type="bibr" rid="bibr67-2040620713498161">Hsu <italic>et al.</italic> 2011</xref>]. The majority of mutations in <italic>GATA2</italic> affect the zinc finger region and are either heterozygous missense mutations or insertion/deletions, implying that a haploinsufficiency model is sufficient for pathogenesis [<xref ref-type="bibr" rid="bibr67-2040620713498161">Hsu <italic>et al.</italic> 2011</xref>].</p>
<p><italic>GATA2</italic> is both a transcription factor involved in hematopoietic stem cell integrity as well as a regulator of phagocytosis by macrophages [<xref ref-type="bibr" rid="bibr163-2040620713498161">Tsai and Orkin, 1997</xref>]. The most common types of opportunistic infections listed to date include mycobacterial disease, fungal infections, and HPV-induced warts. Endogenous defects in macrophages are reported to cause the development of pulmonary alveolar proteinosis, even in the absence of infection.</p>
<p>Patients with MonoMAC syndrome frequently develop MDS but not before several years or even decades of opportunistic infections without any apparent dysplasia in their bone marrow. AML and chronic myelomonocytic leukemia appear to be the most common forms of leukemia in MonoMAC syndrome, and bone marrow transplantation appears to be an effective form of treatment [<xref ref-type="bibr" rid="bibr36-2040620713498161">Cuellar-Rodriguez <italic>et al.</italic> 2011</xref>].</p>
<p>Mutations in <italic>GATA2</italic> have also been recognized to underlie specific forms of congenital neutropenia that evolve into MDS or AML [<xref ref-type="bibr" rid="bibr118-2040620713498161">Pasquet <italic>et al.</italic> 2013</xref>]. In the mild chronic form of congenital neutropenia caused by <italic>GATA2</italic> mutations, the rate of transformation to MDS or AML at 20 years was 54%. Of 14 patients with <italic>GATA2</italic> mutations in the French national registry of chronic neutropenia, less than half displayed the characteristic features of the aforementioned MonoMAC syndrome before evolving into MDS and AML [<xref ref-type="bibr" rid="bibr118-2040620713498161">Pasquet <italic>et al.</italic> 2013</xref>]. Identical <italic>GATA2</italic> mutations in different patients exhibit various outcomes, raising the hypothesis that alternative mechanisms (e.g. cooperative mutations or epigenetic modifications) may play a role in determining phenotype as well [<xref ref-type="bibr" rid="bibr118-2040620713498161">Pasquet <italic>et al.</italic> 2013</xref>].</p>
<p>Recently, Emberger syndrome, an autosomal dominant disorder characterized by primary lymphedema with a predisposition to AML, was also discovered to be associated with mutations in <italic>GATA2</italic> [<xref ref-type="bibr" rid="bibr111-2040620713498161">Ostergaard <italic>et al.</italic> 2011</xref>]. This is not entirely surprising considering <italic>GATA2</italic> has been shown to play an important role in lymphatic development [<xref ref-type="bibr" rid="bibr73-2040620713498161">Kazenwadel <italic>et al.</italic> 2012</xref>]. Interestingly, the majority of <italic>GATA2</italic> mutations in Emberger syndrome are large deletions or nonsense mutations predicted to cause complete loss of function in one allele as opposed to the missense mutations and in-frame insertions seen in the majority of other patients with MonoMAC syndrome without lymphedema. This has led to the hypothesis that the complete deletions seen in Emberger syndrome are more disruptive to lymphatic development compared with the missense mutations seen in MonoMAC syndrome and congenital neutropenia [<xref ref-type="bibr" rid="bibr73-2040620713498161">Kazenwadel <italic>et al.</italic> 2012</xref>].</p>
<p>Of note, clonal cytogenetic abnormalities are a common finding in MonoMAC syndrome, affecting more than 50% of patients. The most frequent abnormality involves monosomy 7, the significance of which is yet to be elucidated [<xref ref-type="bibr" rid="bibr26-2040620713498161">Calvo <italic>et al.</italic> 2011</xref>].</p>
</sec>
<sec id="section6-2040620713498161">
<title>Monosomy 7</title>
<p>Partial or complete loss of chromosome 7 in the leukemic cells of MDS and AML is well established as a poor prognostic factor [<xref ref-type="bibr" rid="bibr15-2040620713498161">Baranger <italic>et al.</italic> 1990</xref>]. In rare cases there have been reports of families in which multiple family members have constitutional loss of chromosome 7 leading to a syndrome with hematologic and neurologic sequelae [<xref ref-type="bibr" rid="bibr30-2040620713498161">Chitambar <italic>et al.</italic> 1983</xref>]. To date, there have been at least 14 pedigrees reported in which multiple family members have had chromosome 7 abnormalities in their bone marrows [<xref ref-type="bibr" rid="bibr49-2040620713498161">Gaitonde <italic>et al.</italic> 2010</xref>]. The pattern of inheritance is typically autosomal dominant and there is a wide variability in terms of disease expression. This heterogeneity underscores our incomplete understanding of the pathogenesis in familial monosomy 7. Several papers have hypothesized that the loss of a tumor suppressor gene on chromosome 7 leads to the development of cytopenias, MDS, and AML, which is frequently seen in these patients at a relatively young age [<xref ref-type="bibr" rid="bibr144-2040620713498161">Shannon <italic>et al.</italic> 1992</xref>; <xref ref-type="bibr" rid="bibr84-2040620713498161">Kratz <italic>et al.</italic> 2001</xref>]. Others hypothesize that a mutator effect resulting in karyotypic instability underlies monosomy 7 [<xref ref-type="bibr" rid="bibr99-2040620713498161">Minelli <italic>et al.</italic> 2001</xref>]. As is true with <italic>de novo</italic> monosomy 7 associated leukemia, the outcome in congenital monosomy 7 associated leukemias is poor and aggressive therapy including swift transplant is often indicated [<xref ref-type="bibr" rid="bibr72-2040620713498161">Kardos <italic>et al.</italic> 2003</xref>].</p>
</sec>
</sec>
<sec id="section7-2040620713498161">
<title>Bone marrow failure syndromes</title>
<p>Inherited bone marrow failure syndromes (IBMFS) are a heterogeneous group of disorders that lead to aplastic anemia and have an increased incidence of malignancy [<xref ref-type="bibr" rid="bibr5-2040620713498161">Alter, 2007</xref>]. Over 80 different genes have been identified as causing one of the IBMFS in several different pathways [<xref ref-type="bibr" rid="bibr1-2040620713498161">Ahmed and Dokal, 2009</xref>; <xref ref-type="bibr" rid="bibr104-2040620713498161">Narla and Ebert, 2010</xref>]. The genes are broadly involved in gatekeeping functions that regulate cell cycle. In general, these cell cycle perturbations lead to p53 activation and cell cycle arrest or senescence [<xref ref-type="bibr" rid="bibr117-2040620713498161">Parikh and Bessler, 2012</xref>]. Several of the genes are also involved in ribosome synthesis and telomere function (<xref ref-type="fig" rid="fig1-2040620713498161">Figure 1</xref>).</p>
<fig id="fig1-2040620713498161" position="float">
<label>Figure 1.</label>
<caption>
<p>Germline syndromes associated with the telomere maintenance and ribosome synthesis pathways.</p>
<p>Schematic diagram detailing the interaction between the telomere maintenance and the ribosome biogenesis pathways. The telomerase complex includes a telomerase reverse transcriptase (TERT) domain as well as a telomerase RNA component (TERC) which enables it to add a six-nucleotide sequence, 5’-TTAGGG, to the 3’ strand of chromosomes [<xref ref-type="bibr" rid="bibr172-2040620713498161">Walne and Dokal, 2009</xref>]. Ribosome synthesis involves synthesis of ribosomal proteins in the nucleus, processing of ribosomal RNA, and assembly of ribosomal proteins with subsequent transport into the cytoplasm [<xref ref-type="bibr" rid="bibr44-2040620713498161">Ellis and Gleizes, 2011</xref>]. Color coding indicates a specific association between a mutated gene and a syndrome that predisposes people to childhood leukemia. Syndromes include dyskeratosis congenita (OMIM 127550, 305000, 224230); Diamond Blackfan anemia (OMIM 105650); and Shwachman–Diamond syndrome (OMIM 260400). Illustration courtesy of Alessandro Baliani. Copyright © 2013. Adapted with permissions from <xref ref-type="bibr" rid="bibr1-2040620713498161">Ahmed and Dokal [2009]</xref>.</p>
</caption>
<graphic xlink:href="10.1177_2040620713498161-fig1.tif"/>
</fig>
<p>All IBMFSs are preleukemic conditions with varying degrees of malignant transformation depending on the underlying disorder. However, the exact mechanism for the increased risk of leukemia development has yet to be elucidated.</p>
<sec id="section8-2040620713498161">
<title>Diamond Blackfan anemia</title>
<p>Diamond Blackfan anemia (DBA) is characterized by a macrocytic anemia that arises in infancy and manifests distinct physical anomalies [<xref ref-type="bibr" rid="bibr38-2040620713498161">Diamond and Blackfan, 1938</xref>; <xref ref-type="bibr" rid="bibr12-2040620713498161">Ball, 2011</xref>]. Craniofacial and urogenital abnormalities are most common, followed by thumb, heart and spinal defects [<xref ref-type="bibr" rid="bibr90-2040620713498161">Lipton <italic>et al.</italic> 2006</xref>]. Failure to thrive is a common finding [<xref ref-type="bibr" rid="bibr168-2040620713498161">Vlachos <italic>et al.</italic> 2008</xref>]. Laboratory features include elevated mean corpuscular volume, hemoglobin F, and erythrocyte adenosine deaminase activity. The majority of cases are sporadic in nature, although there are forms of both autosomal dominant and recessive inheritance [<xref ref-type="bibr" rid="bibr168-2040620713498161">Vlachos <italic>et al.</italic> 2008</xref>]. The first identified mutation in DBA was found on chromosome 19q13 [<xref ref-type="bibr" rid="bibr61-2040620713498161">Gustavsson <italic>et al.</italic> 1997</xref>] in the gene <italic>RPS19</italic> [<xref ref-type="bibr" rid="bibr41-2040620713498161">Draptchinskaia <italic>et al.</italic> 1999</xref>] which encodes a ribosomal protein. Since then, mutations in several other ribosomal protein genes have been recognized with over 200 individual mutations, accounting for nearly half of all DBA cases [<xref ref-type="bibr" rid="bibr19-2040620713498161">Boria <italic>et al.</italic> 2010</xref>]. Recently, exome sequencing analysis of two siblings with clinical DBA were found to have splice site mutations in <italic>GATA1</italic> [<xref ref-type="bibr" rid="bibr138-2040620713498161">Sankaran <italic>et al.</italic> 2012</xref>], a gene encoding for a transcription factor involved in hematopoiesis [<xref ref-type="bibr" rid="bibr162-2040620713498161">Tsai <italic>et al.</italic> 1989</xref>]. These splice site mutations in <italic>GATA1</italic> resulted in impaired production of the full-length form of the protein. This is the first demonstration that mutations outside of genes encoding for ribosomal proteins can be involved in DBA pathogenesis.</p>
<p>Recent work shows that the erythroid compartment has a low threshold for p53 activation and that induction of that pathway leads to selective cycle arrest in erythroid progenitor cells after silencing of the <italic>RPS19</italic> gene [<xref ref-type="bibr" rid="bibr43-2040620713498161">Dutt <italic>et al.</italic> 2011</xref>]. A proposed haploinsufficiency model stipulates that one functional copy of a ribosomal protein is insufficient at producing enough erythropoietic elements to maintain normal red blood cell counts due to inefficient translation [<xref ref-type="bibr" rid="bibr43-2040620713498161">Dutt <italic>et al.</italic> 2011</xref>]. In addition, erythroid cells in DBA have been seen to express alternative spliced variants of <italic>FLVCR1</italic>, which are known to play a role in iron metabolism [<xref ref-type="bibr" rid="bibr130-2040620713498161">Rey <italic>et al.</italic> 2008</xref>]. Free heme toxicity may be partially responsible for the erythroid failure seen in DBA secondary to damage by radical oxygen species. At this point no one single proposed mechanism accounts for all facets of DBA and it is likely that the molecular pathogenesis is multifactorial [<xref ref-type="bibr" rid="bibr12-2040620713498161">Ball, 2011</xref>].</p>
<p>Despite the lack of clarity underlying this disorder, there is a clear predisposition to MDS and AML in patients with DBA with an observed-to-expected ratio of 287 for MDS and 28 for AML [<xref ref-type="bibr" rid="bibr169-2040620713498161">Vlachos <italic>et al.</italic> 2012</xref>]. The most common form of leukemia is AML but rare cases of ALL and lymphoma have been reported [<xref ref-type="bibr" rid="bibr179-2040620713498161">Willig <italic>et al.</italic> 2000</xref>]. Patients are also at increased risk of developing osteogenic sarcoma, which is the most common malignancy reported in the North American DBA registry [<xref ref-type="bibr" rid="bibr91-2040620713498161">Lipton <italic>et al.</italic> 2001</xref>].</p>
</sec>
<sec id="section9-2040620713498161">
<title>Shwachman–Diamond syndrome</title>
<p>Shwachman–Diamond syndrome (SDS) is an autosomal recessive disorder which manifests with anemia in infancy, pancreatic insufficiency, short stature and eventually bone marrow failure [<xref ref-type="bibr" rid="bibr16-2040620713498161">Bodian <italic>et al.</italic> 1964</xref>]. Biallelic mutations in 90% of patients with SDS have been identified to occur in the <italic>SBDS</italic> gene on 7q11.21 [<xref ref-type="bibr" rid="bibr18-2040620713498161">Boocock <italic>et al.</italic> 2003</xref>]. The SBDS protein is involved in several functions, including cell proliferation, mitosis, and maintaining the stromal microenvironment [<xref ref-type="bibr" rid="bibr103-2040620713498161">Myers <italic>et al.</italic> 2013</xref>]. While it has also has been shown that the SBDS protein is involved in ribosomal subunit joining, it is still unclear how this protein is implicated in disease pathogenesis [<xref ref-type="bibr" rid="bibr104-2040620713498161">Narla and Ebert, 2010</xref>; <xref ref-type="bibr" rid="bibr23-2040620713498161">Burwick <italic>et al.</italic> 2012</xref>].</p>
<p>The role that SBDS proteins play in mitotic spindle stability and regulating chromosomal segregation may also lead to the varied cytogenetic abnormalities seen in patients with SDS [<xref ref-type="bibr" rid="bibr10-2040620713498161">Austin <italic>et al.</italic> 2008</xref>]. This chromosomal instability may play a role in the known predisposition of patients with SDS to develop hematologic malignancies. The estimated risk of developing MDS or AML is 19% at 20 years and 36% at 30 years [<xref ref-type="bibr" rid="bibr40-2040620713498161">Donadieu <italic>et al.</italic> 2005</xref>].</p>
</sec>
<sec id="section10-2040620713498161">
<title>Amegakaryocytic thrombocytopenia</title>
<p>Congenital amegakaryocytic thrombocytopenia (CAMT) is an autosomal recessive disorder characterized by isolated thrombocytopenia and progression to pancytopenia. Typically, there are no associated physical exam features, which differentiates CAMT from nearly all other bone marrow failure syndromes and often results in delayed diagnosis [<xref ref-type="bibr" rid="bibr52-2040620713498161">Geddis, 2011</xref>]. Mutations in <italic>c-MPL</italic>, the receptor for thrombopoietin, are responsible for the disorder and lead to high levels of dysfunctional thrombopoietin with low or absent numbers of megakaryocytes in the bone marrow [<xref ref-type="bibr" rid="bibr68-2040620713498161">Ihara <italic>et al.</italic> 1999</xref>]. Two classes of mutations exist, with group CAMT I nonsense mutations leading to persistently low platelet counts and rapid progression to aplastic anemia. Group CAMT II missense mutations are associated with less severe thrombocytopenia and a longer latency to aplasia [<xref ref-type="bibr" rid="bibr55-2040620713498161">Germeshausen <italic>et al.</italic> 2006</xref>]. In a review of 96 patients with CAMT, the rate of malignant transformation was 2% [<xref ref-type="bibr" rid="bibr13-2040620713498161">Ballmaier and Germeshausen, 2011</xref>].</p>
</sec>
<sec id="section11-2040620713498161">
<title>Thrombocytopenia with absent radii syndrome</title>
<p>Thrombocytopenia with absent radii syndrome (TAR) is distinguished on a clinical basis from CAMT by physical exam features, including absent radii but present thumbs. In 2007, it was shown that of 30 patients with TAR examined, all had a deletion at 1q21.1 [<xref ref-type="bibr" rid="bibr79-2040620713498161">Klopocki <italic>et al.</italic> 2007</xref>]. Most recently, TAR became the first recognized human disease caused by mutations in the exon-junction complex (EJC), which is involved in essential RNA processing tasks. In a study of 55 patients with TAR, 53 were caused by compound inheritance of a null allele and one of two low-frequency single nucleotide polymorphisms in the regulatory regions of <italic>RBM8A</italic> that encodes the Y14 subunit of EJC [<xref ref-type="bibr" rid="bibr3-2040620713498161">Albers <italic>et al.</italic> 2012</xref>]. In 75% of cases the mode of inheritance is autosomal recessive in which the 200-kb deleted region is passed on from an unaffected parent, with the remainder of cases occurring as <italic>de novo</italic> mutations. There have been four cases of leukemia (three AML, one ALL) in 300 patients with TAR in the literature [<xref ref-type="bibr" rid="bibr5-2040620713498161">Alter, 2007</xref>].</p>
</sec>
<sec id="section12-2040620713498161">
<title>Dyskeratosis congenita</title>
<p>Dyskeratosis congenita (DC) is a bone marrow failure syndrome with a triad of exam findings, including lacey reticulated pigmentation, dysplastic nails, and oral leukoplakia, although patients frequently present early with only one or two findings [<xref ref-type="bibr" rid="bibr39-2040620713498161">Dokal, 2011</xref>]. Several other manifestations, including pulmonary fibrosis, liver disease, developmental delay and aplastic anemia, occur with varying incidence [<xref ref-type="bibr" rid="bibr140-2040620713498161">Savage and Bertuch, 2010</xref>]. There have been mutations reported in several genes including but not limited to <italic>DKC1, TERC, TERT, NOP10, NHP2, TINF2, C16orf57, RTEL1</italic>, and <italic>TCAB1</italic> which are all involved in telomerase function or the shelterin complex (reviewed by Walne and Dokal) [<xref ref-type="bibr" rid="bibr172-2040620713498161">Walne and Dokal, 2009</xref>; <xref ref-type="bibr" rid="bibr39-2040620713498161">Dokal, 2011</xref>]. However, roughly 50% of all patients with DC do not have a detectable mutation in any of the aforementioned mutations. The mode of inheritance differs with each mutation type and can be autosomal recessive, dominant or X linked. Anticipation is often seen in the autosomal dominant form [<xref ref-type="bibr" rid="bibr140-2040620713498161">Savage and Bertuch, 2010</xref>]. However, identical mutations and telomere length within families have led to different disease phenotypes, suggesting that there are other factors involved in pathogenesis.</p>
<p>Diagnosis now involves Clinical Laboratory Improvement Amendments (CLIA) approved measurement of telomere length via different techniques, including polymerase chain reaction or a flow/fluorescence <italic>in situ</italic> hybridization based approach. Each are technically challenging, the merits of which have been presented [<xref ref-type="bibr" rid="bibr8-2040620713498161">Aubert <italic>et al.</italic> 2012</xref>].</p>
<p>A cohort study from the National Cancer Institute in 2010 reported that 7 out of 50 patients with DC developed leukemia or MDS [<xref ref-type="bibr" rid="bibr6-2040620713498161">Alter <italic>et al.</italic> 2010</xref>]. However, head and neck squamous cell carcinoma remained the most common solid malignancy. Of note, progressive bone marrow failure will occur in up to 80% of patients and is major contributor to premature mortality [<xref ref-type="bibr" rid="bibr39-2040620713498161">Dokal, 2011</xref>].</p>
</sec>
<sec id="section13-2040620713498161">
<title>Severe congenital neutropenia</title>
<p>Severe congenital neutropenia (SCN) encompasses a diverse range of disorders, including Kostmann syndrome which is generally manifest in infants with recurrent infections [<xref ref-type="bibr" rid="bibr82-2040620713498161">Kostmann, 1956</xref>]. The most common form of the disease is autosomal dominant and is related to <italic>ELA2</italic>, which encodes for neutrophil elastase, a serine proteinase involved in neutrophilic function [<xref ref-type="bibr" rid="bibr37-2040620713498161">Dale <italic>et al.</italic> 2000</xref>]. Recently, several other mutations in genes including <italic>HAX1, G6PC3, GFI1, GATA2</italic>, and <italic>WASP</italic> have all been implicated in SCN (reviewed by Klein) [<xref ref-type="bibr" rid="bibr78-2040620713498161">Klein, 2011</xref>]. The latest data on the long-term risk of developing a myeloid malignancy in this population is 2.3% per year after the first decade [<xref ref-type="bibr" rid="bibr136-2040620713498161">Rosenberg <italic>et al.</italic> 2010</xref>].</p>
</sec>
</sec>
<sec id="section14-2040620713498161">
<title>Tumor suppressor gene syndromes</title>
<p>Tumor suppressor genes encode for proteins that have repressive effects on regulation of the cell cycle and promote apoptosis. In the classic ‘two hit hypothesis’, tumor suppressor genes require inactivation in each of the two functioning alleles for malignant transformation.</p>
<sec id="section15-2040620713498161">
<title>Li-Fraumeni syndrome</title>
<p><italic>TP53</italic> is a widely expressed tumor suppressor gene at 17p13.1 that encodes for a protein involved in numerous functions, including activating DNA repair, inducing cell cycle arrest, and initiating apoptosis. Point, missense and nonsense mutations, the majority of which occur in exons 5–8 of <italic>TP53</italic>, are found in diverse cancers [<xref ref-type="bibr" rid="bibr106-2040620713498161">Nigro <italic>et al.</italic> 1989</xref>]. In 1969, Li reported a familial cancer predisposition syndrome with a significantly increased incidence of soft tissue sarcomas, breast cancer, and bone tumors [<xref ref-type="bibr" rid="bibr89-2040620713498161">Li, 1969</xref>]. In 1990 it was subsequently reported that families with ‘Li-Fraumeni syndrome’ (LFS) harbored germline point mutations in <italic>TP53</italic> that, when compounded with somatic <italic>TP53</italic> mutations in target tissues, led to the development of malignancy [<xref ref-type="bibr" rid="bibr95-2040620713498161">Malkin <italic>et al.</italic> 1990</xref>].</p>
<p>In an analysis of 91 families with constitutional <italic>TP53</italic> mutations, 4.2% of patients had developed ALL or lymphoma with an average age of onset at 25.4 years [<xref ref-type="bibr" rid="bibr77-2040620713498161">Kleihues <italic>et al.</italic> 1997</xref>]. In 2013, it was reported that somatic <italic>TP53</italic> alterations are present in 91% of children with low hypodiploid ALL characterized by the presence of 32–39 chromosomes in lymphoblasts [<xref ref-type="bibr" rid="bibr65-2040620713498161">Holmfeldt <italic>et al.</italic> 2013</xref>]. Surprisingly, 43% of these children also harbored germline<italic>TP53</italic> mutations, indicating either an inherited or spontaneous mutation. Several of the identified <italic>TP53</italic> mutations were previously reported in LFS, supporting that hypodiploid leukemia of childhood is a more common malignancy in LFS than previously documented. Similarly, in 2013, whole exome sequencing was performed on a family with five cases of leukemia marked by aneuploidy. Affected family members were found to harbor a germline nonsense mutation in <italic>TP53</italic> [<xref ref-type="bibr" rid="bibr122-2040620713498161">Powell <italic>et al.</italic> 2012</xref>]. Taken together, these recent reports support that the occurrence of hypodiploid ALL in children should prompt testing for LFS.</p>
</sec>
<sec id="section16-2040620713498161">
<title>Neurofibromatosis 1</title>
<p>Neurofibromatosis type 1 (NF1) or von Recklin-ghausen neurofibromatosis is one the most common autosomal dominant disorders primarily affecting the nervous system [<xref ref-type="bibr" rid="bibr46-2040620713498161">Friedman, 1999</xref>]. While NF1 is inherited in 50–70% of cases, the remainder of affected patients represent <italic>de novo</italic> mutations. Common manifestations of the syndrome include, but are not limited to, café-au-lait spots, skinfold freckling, Lisch nodules, optic gliomas, and neurofibromas [<xref ref-type="bibr" rid="bibr178-2040620713498161">Williams <italic>et al.</italic> 2009</xref>]. Neurofibromas are benign tumors of the peripheral nervous system that can eventually transform into malignant peripheral nerve sheath tumors (MPNSTs) [<xref ref-type="bibr" rid="bibr124-2040620713498161">Rasmussen <italic>et al.</italic> 2001</xref>].</p>
<p>The <italic>NF1</italic> gene was discovered by linkage analysis after it was localized to 17q11.2 [<xref ref-type="bibr" rid="bibr28-2040620713498161">Cawthon <italic>et al.</italic> 1990</xref>]. It encodes for the protein neurofibromin which functions as a GTPase-activating protein and is mutated in NF1 [<xref ref-type="bibr" rid="bibr182-2040620713498161">Xu <italic>et al.</italic> 1990</xref>; <xref ref-type="bibr" rid="bibr171-2040620713498161">Wallace <italic>et al.</italic> 1990</xref>]. The Ras family of proteins normally function to control cell differentiation and growth. Neurofibromin functions by hydrolyzing the active Ras-guanidine triphosphate to the inactive Ras-guanidine diphosphate as seen in <xref ref-type="fig" rid="fig2-2040620713498161">Figure 2</xref>. The most frequent malignancies seen in patients with NF1 are optic gliomas, MPNSTs, and astrocytomas [<xref ref-type="bibr" rid="bibr81-2040620713498161">Korf, 2000</xref>]. Leukemia is another cancer that is seen at a higher frequency among patients with NF1 [<xref ref-type="bibr" rid="bibr151-2040620713498161">Stiller <italic>et al.</italic> 1994</xref>]. In contrast to the general population in which 80% of all childhood leukemias are of the lymphoid variety, almost two out of three leukemias diagnosed in patients with NF1 are myeloid in nature. In particular, juvenile myelomonocytic leukemia (JMML) is a rare <italic>RAS</italic>-driven malignancy which is seen at a substantially higher rate (200–500 fold higher) in patients with NF1 compared with the general population [<xref ref-type="bibr" rid="bibr147-2040620713498161">Side <italic>et al.</italic> 1998</xref>].</p>
<fig id="fig2-2040620713498161" position="float">
<label>Figure 2.</label>
<caption>
<p>Germline syndromes associated with the Ras signaling pathway.</p>
<p>Schematic diagram showing the GM-CSF receptor spanning the phospholipid bilayer. After stimulation with a cytokine, the receptor propagates a signaling cascade through the Ras-MAPK, CBL, and JAK-STAT pathways. Neurofibromin, encoded by the gene NF1 is a negative regulator of the Ras pathway by binding to activated Ras and catalyzing GTP hydrolysis, thereby returning Ras to the inactive GDP-bound state. Overall, 1 in 10,000 individuals are affected with an inherited syndrome that is caused by a mutation in the Ras pathway [<xref ref-type="bibr" rid="bibr160-2040620713498161">Tidyman and Rauen, 2012</xref>]. Color coding indicates a specific association between a mutated gene and a syndrome that predisposes children to leukemia. Syndromes include: Noonan syndrome (OMIM 163950); NF1 (OMIM 162200), and CBL syndrome (OMIM 613563). Illustration courtesy of Alessandro Baliani. Copyright © 2013. GDP, guanidine diphosphate; GM-CSF, granulocyte macrophage colony-stimulating factor; GTP, guanidine triphosphate; JAK-STAT, Janus kinase signal transducers and activators of transcription; MAPK, mitogen-activated protein kinase; NF1, neurofibromatosis type 1.</p>
</caption>
<graphic xlink:href="10.1177_2040620713498161-fig2.tif"/>
</fig>
</sec>
<sec id="section17-2040620713498161">
<title>Noonan syndrome</title>
<p>In 1968 Noonan reported on 19 patients who shared similar features including dysmorphic facies, short stature, webbed neck, cryptorchidism and congenital heart abnormalities among other characteristic findings [<xref ref-type="bibr" rid="bibr107-2040620713498161">Noonan, 1968</xref>]. Prior to this report the majority of these patients who were men were diagnosed with ‘the male Turner syndrome‘ due to several overlapping findings between the two syndromes [<xref ref-type="bibr" rid="bibr11-2040620713498161">Avin, 1956</xref>]. In the 1990s the locus for the genetic lesion underlying Noonan syndrome (NS) was mapped to chromosome 12q24.1 and in 2001 it was shown that missense mutations in the gene <italic>PTPN11</italic> are responsible for nearly 50% of cases [<xref ref-type="bibr" rid="bibr156-2040620713498161">Tartaglia <italic>et al.</italic> 2001</xref>]. Since then, several other genes, including <italic>SOS1, RAF1, KRAS, HRAS, BRAF, MEK1/MAP2K1, MEK2/MAP2K2, NRAS, SHOC2, CBL</italic>, and <italic>SPRED1</italic> have been reported in the group of germline disorders now known as ‘Rasopathies’ [<xref ref-type="bibr" rid="bibr7-2040620713498161">Aoki <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr142-2040620713498161">Schubbert <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr135-2040620713498161">Rodriguez-Viciana <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr134-2040620713498161">Roberts <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr127-2040620713498161">Razzaque <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr21-2040620713498161">Brems <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr33-2040620713498161">Cirstea <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr139-2040620713498161">Sarkozy <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr105-2040620713498161">Niemeyer <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr80-2040620713498161">Komatsuzaki <italic>et al.</italic> 2010</xref>]. All of the genes signal in the Ras/Raf/MEK/ERK pathway [<xref ref-type="bibr" rid="bibr133-2040620713498161">Roberts <italic>et al.</italic> 2013</xref>].</p>
<p>One particularly fascinating hematologic consequence of NS is the occurrence in some patients of a transient myeloproliferative neoplasm (MPN) in the first year of life that has many characteristics of JMML. This finding is of particular interest because the association of germline <italic>PTPN11</italic> mutations in the context of NS and MPN led to the discovery that somatic mutations in <italic>PTPN11</italic> are found in 35% of cases of nonsyndromic JMML [<xref ref-type="bibr" rid="bibr157-2040620713498161">Tartaglia <italic>et al.</italic> 2003</xref>; <xref ref-type="bibr" rid="bibr92-2040620713498161">Loh <italic>et al.</italic> 2004</xref>]. However, the spectrum of germline mutations in <italic>PTPN11</italic> is different from the somatic lesions seen in JMML, leading investigators to study and conclude that the biochemical sequelae of the somatic alterations are more severe than the germline alterations. Similar to the transient myeloproliferative disorder (TMD) seen in Down syndrome, most NS/MPN cases do not require any treatment and resolve without intervention [<xref ref-type="bibr" rid="bibr83-2040620713498161">Kratz, 2005</xref>; <xref ref-type="bibr" rid="bibr155-2040620713498161">Tartaglia <italic>et al.</italic> 2006</xref>], though some patients do become symptomatic and require low-dose chemotherapy. In contradistinction to TMD of trisomy 21, there is not an increased risk of developing myeloid neoplasms at a later age as a result of the prior TMD [<xref ref-type="bibr" rid="bibr71-2040620713498161">Jongmans <italic>et al.</italic> 2011</xref>].</p>
</sec>
<sec id="section18-2040620713498161">
<title>CBL syndrome or Noonan syndrome-like disorder</title>
<p>The <italic>CBL</italic> gene located at 11q23.3 encodes for an E3 ubiquitin ligase and multifunction adapter protein of the same name. There are three members of the Cbl family of proteins, <italic>CBL</italic> (c-CBL), <italic>CBL-b</italic>, and <italic>CBL-c</italic> (Cbl-3). Cbl is involved in trafficking and degradation of tyrosine kinases via a ubiquitin ligase function and is involved in many cellular pathways [<xref ref-type="bibr" rid="bibr74-2040620713498161">Keane <italic>et al.</italic> 1999</xref>; <xref ref-type="bibr" rid="bibr141-2040620713498161">Schmidt and Dikic, 2005</xref>]. Missense mutations in the linker region or zinc finger of the <italic>CBL</italic> gene lead to decreased ubiquitination of receptor and nonreceptor tyrosine kinases [<xref ref-type="bibr" rid="bibr25-2040620713498161">Caligiuri <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr137-2040620713498161">Sanada <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr105-2040620713498161">Niemeyer <italic>et al.</italic> 2010</xref>].</p>
<p>A germline syndrome was identified in 2010 characterized by impaired growth, developmental delay, cryptorchidism, deafness and a predisposition to JMML in patients with germline mutations in <italic>CBL</italic> [<xref ref-type="bibr" rid="bibr96-2040620713498161">Martinelli <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr105-2040620713498161">Niemeyer <italic>et al.</italic> 2010</xref>]. As is seen in NF1, 50% of cases are autosomally inherited and 50% occur as <italic>de novo</italic> germline events. Like patients with NS who have germline <italic>PTPN11</italic> mutations predisposing them to the development of transient JMML, patients with germline <italic>CBL</italic> mutations have an increased risk of developing JMML that is frequently, but not uniformly, self-resolving. Unfortunately, even in spontaneously resolving cases, it appears that many of these patients will go on to develop life-threatening vasculitides in the second generation of life [<xref ref-type="bibr" rid="bibr105-2040620713498161">Niemeyer <italic>et al.</italic> 2010</xref>]. Due to the rarity of the reports thus far in the literature, the frequency of malignancies in patients with <italic>CBL</italic> is not yet established.</p>
</sec>
</sec>
<sec id="section19-2040620713498161">
<title>DNA repair defects</title>
<sec id="section20-2040620713498161">
<title>Mismatch repair deficiency syndrome</title>
<p>Lynch syndrome or Hereditary nonpolyposis colon cancer is characterized by early onset colonic and extracolonic malignancies which result from inherited or sporadic mutations in genes responsible for DNA repair [<xref ref-type="bibr" rid="bibr93-2040620713498161">Lynch <italic>et al.</italic> 2006</xref>]. Heterozygous mutations in the mismatch repair genes <italic>MSH2</italic> and <italic>MLH1</italic> account for nearly 90% of cases in Lynch syndrome [<xref ref-type="bibr" rid="bibr120-2040620713498161">Peltomaki and Vasen, 2004</xref>]. While leukemia is not a typical malignancy seen in Lynch syndrome [<xref ref-type="bibr" rid="bibr34-2040620713498161">Cohen, 1992</xref>], there is a variant of this disorder that presents with similar features to NF1 called mismatch repair deficiency syndrome, which is caused by homozygous mutations in one of four mismatch repair genes: <italic>MLH1, MSH2, MSH6</italic>, or <italic>PMS2</italic> [<xref ref-type="bibr" rid="bibr131-2040620713498161">Ricciardone <italic>et al.</italic> 1999</xref>; <xref ref-type="bibr" rid="bibr173-2040620713498161">Wang <italic>et al.</italic> 1999</xref>; <xref ref-type="bibr" rid="bibr180-2040620713498161">Wimmer and Etzler, 2008</xref>]. In 1999, three families were reported in which children displayed homozygous mutations in the <italic>MLH1</italic> gene causing a phenotype similar to NF1 as well as a predisposition to develop hematologic malignancies. In another case report, a child born to consanguineous parents was found to have multiple café au lait spots at the time he was diagnosed with ALL at age 24 months. Although he did not fulfill all the criteria for diagnosis of NF1, his peculiar phenotype prompted a genetic workup which revealed homozygosity for a <italic>MSH2</italic> mutation which he inherited from each of his parents who were heterozygous and asymptomatic [<xref ref-type="bibr" rid="bibr177-2040620713498161">Whiteside <italic>et al.</italic> 2002</xref>]. Since then, more than 70 patients from over 40 families have been characterized with homozygous or compound heterozygous mutations in one of the four MMR genes. Biallelic mutations in <italic>PMS2</italic> account for more than half of all documented cases [<xref ref-type="bibr" rid="bibr180-2040620713498161">Wimmer and Etzler, 2008</xref>]. This syndrome has also been referred to by the acronym CoLoN, alluding to the Colonic tumors, Leukemia/lymphomas, and features of Neurofibromatosis that these patients frequently exhibit [<xref ref-type="bibr" rid="bibr14-2040620713498161">Bandipalliam, 2005</xref>].</p>
</sec>
<sec id="section21-2040620713498161">
<title>Fanconi anemia</title>
<p>Fanconi anemia (FA) is an autosomal recessive disorder characterized by clinical manifestations, including congenital abnormalities, progressive bone marrow failure and propensity to both hematologic and solid cancers [<xref ref-type="bibr" rid="bibr45-2040620713498161">Fanconi, 1967</xref>]. Initial testing for diagnosis involves analysis of chromosomal breakage induced by diepoxybutane (DEB) or other crosslinking agents such as mitomycin C [<xref ref-type="bibr" rid="bibr9-2040620713498161">Auerbach, 2009</xref>]. FA is also categorized by FA complementation status, with eight groups, A–G, including D1 and D2, accounting for more the 90% of all cases (<xref ref-type="fig" rid="fig3-2040620713498161">Figure 3</xref>) [<xref ref-type="bibr" rid="bibr75-2040620713498161">Kee and D’Andrea, 2012</xref>].</p>
<fig id="fig3-2040620713498161" position="float">
<label>Figure 3.</label>
<caption>
<p>Germline syndromes associated with the DNA repair pathway.</p>
<p>Schematic diagram depicting aspects of the DNA repair pathway. Depending on the type of DNA damage that occurs, various pathways including mismatch repair, nucleotide excision repair, base excision repair, homologous recombination repair, and nonhomologous end joining can be employed by cells to repair damaged DNA [<xref ref-type="bibr" rid="bibr20-2040620713498161">Branzei and Foiani, 2008</xref>]. Color coding indicates a specific association between a mutated gene and a syndrome that predisposes children to leukemia. Syndromes include Fanconi anemia (OMIM 227650 and 227645 are the two most common types); ataxia telangiectasia (OMIM 208900); Bloom syndrome (OMIM 210900); Nijmegen breakage syndrome (OMIM 251260); and Werner syndrome (OMIM 277700). Illustration courtesy of Alessandro Baliani. Copyright © 2013. Adapted with permissions from <xref ref-type="bibr" rid="bibr1-2040620713498161">Ahmed and Dokal [2009]</xref>.</p>
</caption>
<graphic xlink:href="10.1177_2040620713498161-fig3.tif"/>
</fig>
<p>Information from the largest FA registry in the United States suggests that roughly 33% of patients with FA will develop a hematologic malignancy by the age of 40, with AML being the most common disease followed by MDS and ALL [<xref ref-type="bibr" rid="bibr86-2040620713498161">Kutler, 2003</xref>]. Patients with FA are also at risk of developing solid cancers such as squamous cell carcinoma (SCC) of the head and neck, vulvar SCC and various types of liver tumors among others. The risk of developing bone marrow failure by the age of 40 approaches 90% without bone marrow transplantation [<xref ref-type="bibr" rid="bibr86-2040620713498161">Kutler, 2003</xref>].</p>
<p>Of particular interest is the occurrence of germline <italic>BRCA2</italic> mutations (Fanconi complementation type D1) in FA. A report detailing six children from five families with FA who developed leukemia at a particularly young age revealed biallelic <italic>BRCA2</italic> mutations [<xref ref-type="bibr" rid="bibr170-2040620713498161">Wagner, 2004</xref>]. These patients had a 40% chance of developing leukemia by the age of 5 compared with patients with non-<italic>BRCA2</italic> FA who carry a 1% risk at the same age. Thus, the occurrence of leukemia in patients with FA at less than 5 years of age should prompt an investigation into the patient’s <italic>BRCA2</italic> locus. Mutations in <italic>BRIP1</italic> and <italic>PALB2</italic> which encode for nuclear binding proteins of BRCA1/2 have also been shown to cause FA-J and FA-N, respectively [<xref ref-type="bibr" rid="bibr88-2040620713498161">Levran <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr128-2040620713498161">Reid <italic>et al.</italic> 2006</xref>]. Most recently, a whole exome analysis of patients with FA without known mutations revealed that several patients harbored biallelic germline mutations in <italic>ERCC4</italic>, previously associated with xeroderma pigmentosum [<xref ref-type="bibr" rid="bibr17-2040620713498161">Bogliolo <italic>et al.</italic> 2013</xref>].</p>
</sec>
<sec id="section22-2040620713498161">
<title>Ataxia telangiectasia</title>
<p>Ataxia telangiectasia (AT) is an autosomal recessive neurodegenerative disorder characterized by progressive ataxia, ocular telangiectasias, immune dysregulation, and a predisposition to lymphoreticular malignancies, in particular after exposure to ionizing radiation [<xref ref-type="bibr" rid="bibr51-2040620713498161">Gatti <italic>et al.</italic> 2001</xref>]. Patients with AT are either homozygous or compound heterozygotes for mutations in the gene ataxia telangiectasia mutated (<italic>ATM</italic>) located on 11q22.3 that results in truncated proteins in the majority of families with AT [<xref ref-type="bibr" rid="bibr59-2040620713498161">Gumy-Pause <italic>et al.</italic> 2003</xref>]. Wild-type <italic>ATM</italic> protein kinases are responsible for repairing double-stranded DNA breaks and coordinating the ensuing cellular response by interacting with p53, BRCA1 and the checkpoint kinase protein (CHK2). Patients with heterozygous germline mutations appear to have a slightly increased risk of developing malignancies [<xref ref-type="bibr" rid="bibr159-2040620713498161">Thompson <italic>et al.</italic> 2005</xref>], although there is considerable debate regarding the exact incidence rates [<xref ref-type="bibr" rid="bibr2-2040620713498161">Ahmed and Rahman, 2006</xref>]. Fifteen percent of 57 sporadic childhood leukemias harbored heterozygous <italic>ATM</italic> mutations in one study [<xref ref-type="bibr" rid="bibr119-2040620713498161">Pause <italic>et al.</italic> 2003</xref>], indicating <italic>ATM</italic> also plays a role as a somatic event. The greatest risk, however, is in patients with biallelic germline mutations who are at increased risk of developing lymphoma and leukemia with observed/expected ratios of between 50 and 750 [<xref ref-type="bibr" rid="bibr100-2040620713498161">Morrell <italic>et al.</italic> 1986</xref>].</p>
<p>Of note, α fetoprotein (AFP) levels are elevated in patients with AT and rise with increasing age [<xref ref-type="bibr" rid="bibr153-2040620713498161">Stray-Pedersen <italic>et al.</italic> 2007</xref>]. AFP can therefore be helpful as an adjunctive diagnostic test of AT in the correct clinical context. When treating leukemia in patients with AT, it is important to remember that ionizing radiation can carry exquisite toxicity in these patients owing to their impaired DNA repair pathway [<xref ref-type="bibr" rid="bibr121-2040620713498161">Pollard and Gatti, 2009</xref>].</p>
</sec>
<sec id="section23-2040620713498161">
<title>Nijmegen breakage syndrome</title>
<p>Nijmegen breakage syndrome (NBS) is another autosomal recessive neurodegenerative disorder with striking similarities to AT, including a strong predisposition to lymphoma and leukemia [<xref ref-type="bibr" rid="bibr176-2040620713498161">Weemaes <italic>et al.</italic> 1981</xref>]. The defining clinical characteristics of NBS include microcephaly, ‘birdlike’ facies, intellectual impairment and growth retardation [<xref ref-type="bibr" rid="bibr31-2040620713498161">Chrzanowska <italic>et al.</italic> 2012</xref>]. In one study of 26 patients with NBS, nearly 50% had developed a malignancy, with lymphoma being the most highly represented [<xref ref-type="bibr" rid="bibr85-2040620713498161">Krüger <italic>et al.</italic> 2007</xref>]. The underlying mutation in <italic>NBS1</italic> is distinct from AT [<xref ref-type="bibr" rid="bibr165-2040620713498161">Varon <italic>et al.</italic> 1998</xref>], although the mutated proteins in both disorders interact with each other as part of the double-stranded breakage repair complex called MRN (Mre11, Rad50, and Nbs1 proteins) [<xref ref-type="bibr" rid="bibr27-2040620713498161">Carney <italic>et al.</italic> 1998</xref>; <xref ref-type="bibr" rid="bibr87-2040620713498161">Lee and Paull, 2005</xref>]. The degree of truncation in the Nbs1 protein inversely correlates with the risk of developing cancer [<xref ref-type="bibr" rid="bibr85-2040620713498161">Krüger <italic>et al.</italic> 2007</xref>]. NBS1 functions as a hypomorphic protein and even in its truncated form has been shown to bind to MRE11 and RAD50 to stimulate ATM and its downstream targets. Therefore, patients with the lowest expression of NBS1 will be at increased risk of potential progression to malignancy via downregulation of double-strand DNA breaks and decreased interaction with p53 and CHK2 [<xref ref-type="bibr" rid="bibr85-2040620713498161">Krüger <italic>et al.</italic> 2007</xref>].</p>
</sec>
<sec id="section24-2040620713498161">
<title>Bloom syndrome</title>
<p>Bloom syndrome (BS) is an autosomal recessive disorder most common among Ashkenazi Jews [<xref ref-type="bibr" rid="bibr132-2040620713498161">Roa <italic>et al.</italic> 1999</xref>] which is characterized by growth retardation, photosensitivity rashes and predisposition to malignancy at an early age [<xref ref-type="bibr" rid="bibr53-2040620713498161">German, 1995</xref>]. The genetic defect is in the <italic>BLM</italic> gene which resides at 15q26.1 [<xref ref-type="bibr" rid="bibr152-2040620713498161">Straughen <italic>et al.</italic> 1996</xref>] and encodes a protein in the RecQ helicase family which is postulated to support genomic stability in the face of DNA damage [<xref ref-type="bibr" rid="bibr29-2040620713498161">Cheok <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr32-2040620713498161">Chu and Hickson, 2009</xref>]. Lymphoma and leukemia are the two most common types of cancers seen in patients with BS, although in contrast to other DNA repair defect syndromes, patients with BS develop a wide spectrum of malignancies similar to the general population but at an earlier age [<xref ref-type="bibr" rid="bibr54-2040620713498161">German, 1997</xref>]. In a report summarizing malignancies detected in a BS registry, there were 21 instances of leukemia documented in 168 patients [<xref ref-type="bibr" rid="bibr54-2040620713498161">German, 1997</xref>].</p>
<p>Werner syndrome and Rothmund–Thomson syndrome (RTS) are similar disorders caused by mutations in <italic>WRN</italic> [<xref ref-type="bibr" rid="bibr58-2040620713498161">Gray <italic>et al.</italic> 1997</xref>] and <italic>RECQL4</italic> [<xref ref-type="bibr" rid="bibr47-2040620713498161">Furuichi <italic>et al.</italic> 1999</xref>], respectively, which are also members of the RecQ helicase family. Werner syndrome is remarkable for premature aging in addition to overlapping features with BS. Of note, soft tissue sarcomas are the most common malignancy in Werner syndrome, while osteosarcoma is the most common in RTS [<xref ref-type="bibr" rid="bibr57-2040620713498161">Goto <italic>et al.</italic> 1996</xref>; <xref ref-type="bibr" rid="bibr174-2040620713498161">Wang <italic>et al.</italic> 2001</xref>]. RAPADILINO syndrome is another disorder related to the RecQ family, characterized by mutations in <italic>RECQL4</italic> and is inherited in an autosomal dominant fashion. Typical features include short stature, infantile diarrhea, patellar hypoplasia, and radial ray anomalies, but not poikiloderma as is common in RTS. In one study of 15 patients with RAPADILINO syndrome, four had developed lymphoma and two had developed osteosarcoma [<xref ref-type="bibr" rid="bibr148-2040620713498161">Siitonen <italic>et al.</italic> 2008</xref>].</p>
</sec>
</sec>
<sec id="section25-2040620713498161">
<title>Immunodeficiency syndromes</title>
<p>Patients with primary inherited immunodeficiencies are at risk of developing malignancies at significantly higher rates than the general population [<xref ref-type="bibr" rid="bibr145-2040620713498161">Shapiro, 2010</xref>]. Risks vary depending on the type of immunodeficiency and malignancy but the lifetime incidence has been reported in the 4–25% range [<xref ref-type="bibr" rid="bibr101-2040620713498161">Mueller and Pizzo, 1995</xref>]. In addition to the increased risk of infection, Epstein Barr virus in particular predisposes patients who are immunocompromised to develop lymphoma, which is the most common type of malignancy seen in this population. Other viral infections could activate proto-oncogenes in the host via transduction or stimulate transcription factors that induce oncogenesis.</p>
<sec id="section26-2040620713498161">
<title>Wiskott–Aldrich syndrome</title>
<p>Wiskott–Aldrich syndrome (WAS) is an X-linked disorder characterized by the triad of thrombocytopenia, primary immunodeficiency, and eczema along with a predisposition to autoimmunity and malignancy [<xref ref-type="bibr" rid="bibr4-2040620713498161">Albert <italic>et al.</italic> 2011</xref>]. There is tremendous clinical variability in this disorder that is closely related to the type of underlying mutation in the WAS protein which functions in regulating actin polymerization in hematopoietic cells [<xref ref-type="bibr" rid="bibr108-2040620713498161">Ochs and Thrasher, 2006</xref>]. Classic WAS that presents with the clinical triad is most often seen when mutations in the <italic>WASP</italic> gene lead to an absent or truncated form of the protein. If the WAS protein is normal in size despite the underlying mutation, it more frequently results in other phenotypes, including X-linked thrombocytopenia without immunodeficiency or X-linked neutropenia [<xref ref-type="bibr" rid="bibr166-2040620713498161">Villa <italic>et al.</italic> 1995</xref>; <xref ref-type="bibr" rid="bibr69-2040620713498161">Jin <italic>et al.</italic> 2004</xref>].</p>
<p>Approximately 70% of patients with WAS will develop at least one autoimmune disorder, most commonly, hemolytic anemia [<xref ref-type="bibr" rid="bibr42-2040620713498161">Dupuis-Girod <italic>et al.</italic> 2003</xref>]. Roughly 13% of patients with WAS will develop at least one malignancy, with lymphoma being the most prevalent subtype. Autoimmunity appears to be the single most important risk factor for developing a malignancy in this patient population [<xref ref-type="bibr" rid="bibr42-2040620713498161">Dupuis-Girod <italic>et al.</italic> 2003</xref>]. Based on a seminal survey, 25% of patients with WAS who had an autoimmune component to their disorder developed a malignancy, while only 5% of patients who did not display autoimmune phenomenon developed a malignancy [<xref ref-type="bibr" rid="bibr154-2040620713498161">Sullivan <italic>et al.</italic> 1994</xref>]. The mechanism for this association has yet to be elucidated.</p>
</sec>
<sec id="section27-2040620713498161">
<title>Bruton agammaglobulinemia</title>
<p>Bruton agammaglobulinemia, also referred to as X-linked agammaglobulinemia (XLA), is a primary immunodeficiency caused by mutations in the Bruton tyrosine kinase (<italic>BTK</italic>) gene at Xq21.3-22 [<xref ref-type="bibr" rid="bibr22-2040620713498161">Bruton, 1952</xref>; <xref ref-type="bibr" rid="bibr164-2040620713498161">Väliaho <italic>et al.</italic> 2006</xref>]. The mutated gene, normally responsible for B-cell maturation, causes arrest of B cells before maturing into plasma cells capable of producing immunoglobulins [<xref ref-type="bibr" rid="bibr126-2040620713498161">Rawlings and Witte, 1994</xref>]. There are hundreds of reported mutations in the <italic>BTK</italic> gene leading to XLA. Most are missense, resulting in varying degrees of enzymatic function [<xref ref-type="bibr" rid="bibr35-2040620713498161">Conley <italic>et al.</italic> 2005</xref>]. As early as 1963, it was recognized that leukemia and lymphoma occurred more frequently in patients with XLA than the population at large [<xref ref-type="bibr" rid="bibr116-2040620713498161">Page <italic>et al.</italic> 1963</xref>]. However, surveying a more recent registry of 201 patients with XLA in the United States, only four patients were noted to have a history of malignancy, with one case each of osteosarcoma, lymphoma, adenocarcinoma of the lung, and reticulum cell sarcoma [<xref ref-type="bibr" rid="bibr181-2040620713498161">Winkelstein <italic>et al.</italic> 2006</xref>]. Thus, the exact incidence of leukemia and lymphoma in this condition is not clear at this time.</p>
</sec>
</sec>
<sec id="section28-2040620713498161">
<title>Down syndrome and hematologic malignancies</title>
<p>Constitutional trisomy of chromosome 21 carries the risk of several unique hematologic sequelae [<xref ref-type="bibr" rid="bibr125-2040620713498161">Ravindranath, 2004</xref>]. First, approximately 10% of patients with Down syndrome will develop a TMD that frequently self resolves [<xref ref-type="bibr" rid="bibr97-2040620713498161">Massey, 2004</xref>]. However, TMD in patients with risk factors for adverse outcomes such as premature infants, those with high white blood cell counts and those with visceromegaly often require AML like chemotherapy [<xref ref-type="bibr" rid="bibr50-2040620713498161">Gamis, 2004</xref>]. Approximately 30% of babies with Down syndrome and a history of TMD will develop MDS or AML. <italic>De novo</italic> AML is treated less aggressively in patients with Down syndrome due to their exquisite sensitivity to chemotherapy, both in terms of response and potential for toxicity. Bone marrow transplant is rarely employed in patients with trisomy 21, except in the most aggressive of all cases. The overall incidence of leukemia in Down syndrome is roughly 2%, which is 10–100 times higher than the general population [<xref ref-type="bibr" rid="bibr63-2040620713498161">Hasle <italic>et al.</italic> 2000</xref>]. Interestingly the incidence of almost all other malignancies with the exception of retinoblastoma and germ cell tumors is markedly lower in the Down syndrome population. In general, the distribution of leukemia between ALL and AML in people with Down syndrome is similar to that of the general population (85% ALL), except in the first 3 years of life when AML predominates, with amegakaryoblastic leukemia (AMKL) presenting as the most common form. AMKL is characterized by <italic>GATA1</italic> mutations, which normally encodes for a transcription factor important in erythroid and megakaryocyte development [<xref ref-type="bibr" rid="bibr175-2040620713498161">Wechsler <italic>et al.</italic> 2002</xref>].</p>
<p>Patients with trisomy 21 are also at increased risk of developing ALL. Recently, <italic>JAK2</italic> mutations as well high expression levels of the cytokine receptor <italic>CRLF2</italic> have been found in 19% and 66% of patients with Down syndrome and ALL, respectively [<xref ref-type="bibr" rid="bibr102-2040620713498161">Mullighan <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr64-2040620713498161">Hertzberg <italic>et al.</italic> 2010</xref>]. Overexpression of <italic>CRLF2</italic> is associated with genomic lesions of <italic>CRLF2</italic>, most notably in people with Down’s syndrome, of a PAR1 deletion that fuses the <italic>P2RY8</italic> gene located on the pseudo autosomal regions of the sex chromosomes with the <italic>CRFL2</italic> gene.</p>
<p>Proposed mechanisms for the increased incidence of leukemia in patients with trisomy 21 involve genes on chromosome 21 including cystathionine β synthase (<italic>CBS</italic>), which is thought to act on the folate pathway and superoxide dismutase (<italic>SOD1</italic>), which is suspected to increase DNA damage and lead to the aforementioned <italic>GATA1</italic> mutations [<xref ref-type="bibr" rid="bibr24-2040620713498161">Cabelof <italic>et al.</italic> 2009</xref>]. While a putative tumor suppressor gene on chromosome 21 has been postulated to increase the risk of leukemia, a specific disomic homozygous mutation has yet to be elucidated [<xref ref-type="bibr" rid="bibr158-2040620713498161">Taub, 2004</xref>]. The genetic basis for the increased predisposition to leukemia but protection from solid malignancies is not well understood at this time [<xref ref-type="bibr" rid="bibr94-2040620713498161">Malinge <italic>et al.</italic> 2009</xref>].</p>
</sec>
<sec id="section29-2040620713498161">
<title>Germline polymorphisms</title>
<p>There has been an explosion of genome-wide association studies that identify inherited single nucleotide polymorphisms (SNPs) that are associated with the development of human diseases, including childhood leukemia, as well as predicting response to therapy and/or relapse [<xref ref-type="bibr" rid="bibr183-2040620713498161">Yang, 2009</xref>; <xref ref-type="bibr" rid="bibr109-2040620713498161">Orsi <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr184-2040620713498161">Yang <italic>et al.</italic> 2012</xref>]. Polymorphisms in <italic>IKZF1, CDKN2A, ARID5B</italic> and <italic>CEBPE</italic> have all been shown to influence the risk of developing ALL in children [<xref ref-type="bibr" rid="bibr161-2040620713498161">Treviño <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr146-2040620713498161">Sherborne <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr109-2040620713498161">Orsi <italic>et al.</italic> 2012</xref>]. While these associations are statistically significant, they are still modest in terms of relative risk, confirming that risk factors for developing ALL are polygenic in nature. SNPs in the genes <italic>PYGL</italic> and <italic>PDE4B</italic> have also been shown to influence risk of response to therapy [<xref ref-type="bibr" rid="bibr184-2040620713498161">Yang <italic>et al.</italic> 2012</xref>]. These genes are responsible for metabolism of several chemotherapeutics used in treatment of childhood ALL, and are therefore logical determinants of outcome [<xref ref-type="bibr" rid="bibr185-2040620713498161">Zaza <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr76-2040620713498161">Kim <italic>et al.</italic> 2011</xref>].</p>
</sec>
<sec id="section30-2040620713498161">
<title>Future directions</title>
<p>Cancer predisposition syndromes have become increasingly recognized through thoughtful collaborations between clinicians and scientists. Through advances in next-generation sequencing technologies, new germline mutations that alter proteins responsible for critical cellular functions have been identified. These discoveries are critical to facilitate early diagnoses for families and clinicians, which have obvious implications for cancer surveillance and genetic counseling. In addition, the discovery of these alterations has revealed commonly altered pathways in a number of genes, yielding new insights into the biological mechanisms underpinning these disorders. Ultimately, we hope and anticipate that novel therapies will arise for these patients as continued progress is made.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This work was supported by the Leukemia and Lymphoma Society (grant number 6059-09 to MLL), NIH (grant number T32 CA128583-6 to ES), the Frank A. Campini Foundation (to MLL), and the Team Conner Foundation.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare no conflicts of interest in preparing this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>M.</given-names></name>
<name><surname>Dokal</surname><given-names>I.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Understanding aplastic anaemia/bone-marrow failure syndromes</article-title>. <source>Paediatr Child Health</source> <volume>19</volume>: <fpage>351</fpage>–<lpage>357</lpage>.</citation>
</ref>
<ref id="bibr2-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>M.</given-names></name>
<name><surname>Rahman</surname><given-names>N.</given-names></name>
</person-group> (<year>2006</year>) <article-title>ATM and breast cancer susceptibility</article-title>. <source>Oncogene</source> <volume>25</volume>: <fpage>5906</fpage>–<lpage>5911</lpage>.</citation>
</ref>
<ref id="bibr3-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Albers</surname><given-names>C.</given-names></name>
<name><surname>Paul</surname><given-names>D.</given-names></name>
<name><surname>Schulze</surname><given-names>H.</given-names></name>
<name><surname>Freson</surname><given-names>K.</given-names></name>
<name><surname>Stephens</surname><given-names>J.</given-names></name>
<name><surname>Smethurst</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndrome</article-title>. <source>Nat Genet</source> <volume>44</volume>: <fpage>435</fpage>–<lpage>439</lpage>.</citation>
</ref>
<ref id="bibr4-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Albert</surname><given-names>M.</given-names></name>
<name><surname>Notarangelo</surname><given-names>L.</given-names></name>
<name><surname>Ochs</surname><given-names>H.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Clinical spectrum, pathophysiology and treatment of the Wiskott–Aldrich syndrome</article-title>. <source>Curr Opin Hematol</source> <volume>18</volume>: <fpage>42</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr5-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alter</surname><given-names>B.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Diagnosis, genetics, and management of inherited bone marrow failure syndromes</article-title>. <source>Hematology Am Soc Hematol Educ Program</source> <volume>2007</volume>: <fpage>29</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr6-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alter</surname><given-names>B.</given-names></name>
<name><surname>Giri</surname><given-names>N.</given-names></name>
<name><surname>Savage</surname><given-names>S.</given-names></name>
<name><surname>Peters</surname><given-names>J.</given-names></name>
<name><surname>Loud</surname><given-names>J.</given-names></name>
<name><surname>Leathwood</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study</article-title>. <source>Br J Haematol</source> <volume>150</volume>: <fpage>179</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr7-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aoki</surname><given-names>Y.</given-names></name>
<name><surname>Niihori</surname><given-names>T.</given-names></name>
<name><surname>Kawame</surname><given-names>H.</given-names></name>
<name><surname>Kurosawa</surname><given-names>K.</given-names></name>
<name><surname>Ohashi</surname><given-names>H.</given-names></name>
<name><surname>Tanaka</surname><given-names>Y.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Germline mutations in HRAS proto-oncogene cause Costello syndrome</article-title>. <source>Nat Genet</source> <volume>37</volume>: <fpage>1038</fpage>–<lpage>1040</lpage>.</citation>
</ref>
<ref id="bibr8-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aubert</surname><given-names>G.</given-names></name>
<name><surname>Hills</surname><given-names>M.</given-names></name>
<name><surname>Lansdorp</surname><given-names>P.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Telomere length measurement—caveats and a critical assessment of the available technologies and tools</article-title>. <source>Mutat Res</source> <volume>730</volume>: <fpage>59</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr9-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Auerbach</surname><given-names>A.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Fanconi anemia and its diagnosis</article-title>. <source>Mutat Res</source> <volume>668</volume>: <fpage>4</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr10-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Austin</surname><given-names>K.</given-names></name>
<name><surname>Gupta</surname><given-names>M.</given-names><suffix>Jr</suffix></name>
<name><surname>Coats</surname><given-names>S.</given-names></name>
<name><surname>Tulpule</surname><given-names>A.</given-names></name>
<name><surname>Mostoslavsky</surname><given-names>G.</given-names></name>
<name><surname>Balazs</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Mitotic spindle destabilization and genomic instability in Shwachman–Diamond syndrome</article-title>. <source>J Clin Invest</source> <volume>118</volume>: <fpage>1511</fpage>–<lpage>1518</lpage>.</citation>
</ref>
<ref id="bibr11-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Avin</surname><given-names>J.</given-names></name>
</person-group> (<year>1956</year>) <article-title>The male Turner syndrome</article-title>. <source>Arch Pediatr Adolesc Med</source> <volume>91</volume>: <fpage>630</fpage>.</citation>
</ref>
<ref id="bibr12-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ball</surname><given-names>S.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Diamond Blackfan anemia</article-title>. <source>Hematology Am Soc Hematol Educ Program</source> <volume>2011</volume>: <fpage>487</fpage>–<lpage>491</lpage>.</citation>
</ref>
<ref id="bibr13-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ballmaier</surname><given-names>M.</given-names></name>
<name><surname>Germeshausen</surname><given-names>M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment</article-title>. <source>Semin Thromb Hemost</source> <volume>37</volume>: <fpage>673</fpage>–<lpage>681</lpage>.</citation>
</ref>
<ref id="bibr14-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bandipalliam</surname><given-names>P.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Syndrome of early onset colon cancers, hematologic malignancies &amp; features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations</article-title>. <source>Fam Cancer</source> <volume>4</volume>: <fpage>323</fpage>–<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr15-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baranger</surname><given-names>L.</given-names></name>
<name><surname>Baruchel</surname><given-names>A.</given-names></name>
<name><surname>Leverger</surname><given-names>G.</given-names></name>
<name><surname>Schaison</surname><given-names>G.</given-names></name>
<name><surname>Berger</surname><given-names>C.</given-names></name>
</person-group> (<year>1990</year>) <article-title>Monosomy-7 in childhood hemopoietic disorders</article-title>. <source>Leukemia</source> <volume>4</volume>: <fpage>345</fpage>–<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr16-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bodian</surname><given-names>M.</given-names></name>
<name><surname>Sheldon</surname><given-names>W.</given-names></name>
<name><surname>Lightwood</surname><given-names>R.</given-names></name>
</person-group> (<year>1964</year>) <article-title>Congenital hypoplasia of the exocrine pancreas</article-title>. <source>Acta Paediatr</source> <volume>53</volume>: <fpage>282</fpage>–<lpage>293</lpage>.</citation>
</ref>
<ref id="bibr17-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bogliolo</surname><given-names>M.</given-names></name>
<name><surname>Schuster</surname><given-names>B.</given-names></name>
<name><surname>Stoepker</surname><given-names>C.</given-names></name>
<name><surname>Derkunt</surname><given-names>B.</given-names></name>
<name><surname>Su</surname><given-names>Y.</given-names></name>
<name><surname>Raams</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2013</year>) <article-title>Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia</article-title>. <source>Am J Med Genet</source> <volume>92</volume>: <fpage>800</fpage>–<lpage>806</lpage>.</citation>
</ref>
<ref id="bibr18-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boocock</surname><given-names>G.</given-names></name>
<name><surname>Morrison</surname><given-names>J.</given-names></name>
<name><surname>Popovic</surname><given-names>M.</given-names></name>
<name><surname>Richards</surname><given-names>N.</given-names></name>
<name><surname>Ellis</surname><given-names>L.</given-names></name>
<name><surname>Durie</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Mutations in SBDS are associated with Shwachman–Diamond syndrome</article-title>. <source>Nat Genet</source> <volume>33</volume>: <fpage>97</fpage>–<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr19-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boria</surname><given-names>I.</given-names></name>
<name><surname>Garelli</surname><given-names>E.</given-names></name>
<name><surname>Gazda</surname><given-names>H.</given-names></name>
<name><surname>Aspesi</surname><given-names>A.</given-names></name>
<name><surname>Quarello</surname><given-names>P.</given-names></name>
<name><surname>Pavesi</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>The ribosomal basis of Diamond–Blackfan anemia: mutation and database update</article-title>. <source>Hum Mutat</source> <volume>31</volume>: <fpage>1269</fpage>–<lpage>1279</lpage>.</citation>
</ref>
<ref id="bibr20-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Branzei</surname><given-names>D.</given-names></name>
<name><surname>Foiani</surname><given-names>M.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Regulation of DNA repair throughout the cell cycle</article-title>. <source>Nat Rev Mol Cell Biol</source> <volume>9</volume>: <fpage>297</fpage>–<lpage>308</lpage>.</citation>
</ref>
<ref id="bibr21-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brems</surname><given-names>H.</given-names></name>
<name><surname>Chmara</surname><given-names>M.</given-names></name>
<name><surname>Sahbatou</surname><given-names>M.</given-names></name>
<name><surname>Denayer</surname><given-names>E.</given-names></name>
<name><surname>Taniguchi</surname><given-names>K.</given-names></name>
<name><surname>Kato</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1–like phenotype</article-title>. <source>Nat Genet</source> <volume>39</volume>: <fpage>1120</fpage>–<lpage>1126</lpage>.</citation>
</ref>
<ref id="bibr22-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bruton</surname><given-names>O.</given-names></name>
</person-group> (<year>1952</year>) <article-title>Agammaglobulinemia</article-title>. <source>Pediatrics</source> <volume>9</volume>: <fpage>722</fpage>–<lpage>728</lpage>.</citation>
</ref>
<ref id="bibr23-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burwick</surname><given-names>N.</given-names></name>
<name><surname>Coats</surname><given-names>S.</given-names></name>
<name><surname>Nakamura</surname><given-names>T.</given-names></name>
<name><surname>Shimamura</surname><given-names>A.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Impaired ribosomal subunit association in Shwachman–Diamond syndrome</article-title>. <source>Blood</source> <volume>120</volume>: <fpage>5143</fpage>–<lpage>5152</lpage>.</citation>
</ref>
<ref id="bibr24-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cabelof</surname><given-names>D.</given-names></name>
<name><surname>Patel</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>van Remmen</surname><given-names>H.</given-names></name>
<name><surname>Matherly</surname><given-names>L.</given-names></name>
<name><surname>Ge</surname><given-names>Y.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome</article-title>. <source>Blood</source> <volume>114</volume>: <fpage>2753</fpage>–<lpage>2763</lpage>.</citation>
</ref>
<ref id="bibr25-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caligiuri</surname><given-names>M.</given-names></name>
<name><surname>Briesewitz</surname><given-names>R.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Wei</surname><given-names>M.</given-names></name>
<name><surname>Arnoczky</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia</article-title>. <source>Blood</source> <volume>110</volume>: <fpage>1022</fpage>–<lpage>1024</lpage>.</citation>
</ref>
<ref id="bibr26-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calvo</surname><given-names>K.</given-names></name>
<name><surname>Vinh</surname><given-names>D.</given-names></name>
<name><surname>Maric</surname><given-names>I.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Noel</surname><given-names>P.</given-names></name>
<name><surname>Stetler-Stevenson</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications</article-title>. <source>Haematologica</source> <volume>96</volume>: <fpage>1221</fpage>–<lpage>1225</lpage>.</citation>
</ref>
<ref id="bibr27-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carney</surname><given-names>J.</given-names></name>
<name><surname>Maser</surname><given-names>R.</given-names></name>
<name><surname>Olivares</surname><given-names>H.</given-names></name>
<name><surname>Davis</surname><given-names>E.</given-names></name>
<name><surname>Le Beau</surname><given-names>M.</given-names></name>
<name><surname>Yates</surname><given-names>J.</given-names><suffix>3rd</suffix></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response</article-title>. <source>Cell</source> <volume>93</volume>: <fpage>477</fpage>–<lpage>486</lpage>.</citation>
</ref>
<ref id="bibr28-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cawthon</surname><given-names>R.</given-names></name>
<name><surname>Weiss</surname><given-names>R.</given-names></name>
<name><surname>Xu</surname><given-names>G.</given-names></name>
<name><surname>Viskochil</surname><given-names>D.</given-names></name>
<name><surname>Culver</surname><given-names>M.</given-names></name>
<name><surname>Stevens</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>1990</year>) <article-title>A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations</article-title>. <source>Cell</source> <volume>62</volume>: <fpage>193</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr29-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cheok</surname><given-names>C.</given-names></name>
<name><surname>Bachrati</surname><given-names>C.</given-names></name>
<name><surname>Chan</surname><given-names>K.</given-names></name>
<name><surname>Ralf</surname><given-names>C.</given-names></name>
<name><surname>Wu</surname><given-names>L.</given-names></name>
<name><surname>Hickson</surname><given-names>I.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Roles of the Bloom’s syndrome helicase in the maintenance of genome stability</article-title>. <source>Biochem Soc Trans</source> <volume>33</volume>: <fpage>1456</fpage>–<lpage>1459</lpage>.</citation>
</ref>
<ref id="bibr30-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chitambar</surname><given-names>C.</given-names></name>
<name><surname>Robinson</surname><given-names>W.</given-names></name>
<name><surname>Glode</surname><given-names>L.</given-names></name>
</person-group> (<year>1983</year>) <article-title>Familial leukemia and aplastic anemia associated with monosomy 7</article-title>. <source>Am J Med</source> <volume>75</volume>: <fpage>756</fpage>–<lpage>762</lpage>.</citation>
</ref>
<ref id="bibr31-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chrzanowska</surname><given-names>K.</given-names></name>
<name><surname>Gregorek</surname><given-names>H.</given-names></name>
<name><surname>Dembowska-Bagińska</surname><given-names>B.</given-names></name>
<name><surname>Kalina</surname><given-names>M.</given-names></name>
<name><surname>Digweed</surname><given-names>M.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Nijmegen breakage syndrome (NBS)</article-title>. <source>Orphanet J Rare Dis</source> <volume>7</volume>: <fpage>13</fpage>.</citation>
</ref>
<ref id="bibr32-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chu</surname><given-names>W.</given-names></name>
<name><surname>Hickson</surname><given-names>I.</given-names></name>
</person-group> (<year>2009</year>) <article-title>RecQ helicases: multifunctional genome caretakers</article-title>. <source>Nat Rev Cancer</source> <volume>9</volume>: <fpage>644</fpage>–<lpage>654</lpage>.</citation>
</ref>
<ref id="bibr33-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cirstea</surname><given-names>I.</given-names></name>
<name><surname>Kutsche</surname><given-names>K.</given-names></name>
<name><surname>Dvorsky</surname><given-names>R.</given-names></name>
<name><surname>Gremer</surname><given-names>L.</given-names></name>
<name><surname>Carta</surname><given-names>C.</given-names></name>
<name><surname>Horn</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>A restricted spectrum of NRAS mutations causes Noonan syndrome</article-title>. <source>Nat Genet</source> <volume>42</volume>: <fpage>27</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr34-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>P.</given-names></name>
</person-group> (<year>1992</year>) <article-title>Muir–Torre syndrome in patients with hematologic malignancies</article-title>. <source>Am J Hematol</source> <volume>40</volume>: <fpage>64</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr35-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Conley</surname><given-names>M.</given-names></name>
<name><surname>Broides</surname><given-names>A.</given-names></name>
<name><surname>Hernandez-Trujillo</surname><given-names>V.</given-names></name>
<name><surname>Howard</surname><given-names>V.</given-names></name>
<name><surname>Kanegane</surname><given-names>H.</given-names></name>
<name><surname>Miyawaki</surname><given-names>T.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Genetic analysis of patients with defects in early B-cell development</article-title>. <source>Immunol Rev</source> <volume>203</volume>: <fpage>216</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr36-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cuellar-Rodriguez</surname><given-names>J.</given-names></name>
<name><surname>Gea-Banacloche</surname><given-names>J.</given-names></name>
<name><surname>Freeman</surname><given-names>A.</given-names></name>
<name><surname>Hsu</surname><given-names>A.</given-names></name>
<name><surname>Zerbe</surname><given-names>C.</given-names></name>
<name><surname>Calvo</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency</article-title>. <source>Blood</source> <volume>118</volume>: <fpage>3715</fpage>–<lpage>3720</lpage>.</citation>
</ref>
<ref id="bibr37-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dale</surname><given-names>D.</given-names></name>
<name><surname>Person</surname><given-names>R.</given-names></name>
<name><surname>Bolyard</surname><given-names>A.</given-names></name>
<name><surname>Aprikyan</surname><given-names>A.</given-names></name>
<name><surname>Bos</surname><given-names>C.</given-names></name>
<name><surname>Bonilla</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia</article-title>. <source>Blood</source> <volume>96</volume>: <fpage>2317</fpage>–<lpage>2322</lpage>.</citation>
</ref>
<ref id="bibr38-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Diamond</surname><given-names>L.</given-names></name>
<name><surname>Blackfan</surname><given-names>K.</given-names></name>
</person-group> (<year>1938</year>) <article-title>Hypoplastic Anemia</article-title>. <source>Am J Dis Child</source> <fpage>464</fpage>–<lpage>467</lpage>.</citation>
</ref>
<ref id="bibr39-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dokal</surname><given-names>I.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Dyskeratosis congenita</article-title>. <source>Hematology Am Soc Hematol Educ Program</source> <volume>2011</volume>: <fpage>480</fpage>–<lpage>486</lpage>.</citation>
</ref>
<ref id="bibr40-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Donadieu</surname><given-names>J.</given-names></name>
<name><surname>Leblanc</surname><given-names>T.</given-names></name>
<name><surname>Meunier</surname><given-names>B.</given-names></name>
<name><surname>Barkaoui</surname><given-names>M.</given-names></name>
<name><surname>Fenneteau</surname><given-names>O.</given-names></name>
<name><surname>Bertrand</surname><given-names>Y.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group</article-title>. <source>Haematologica</source> <volume>90</volume>: <fpage>45</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr41-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Draptchinskaia</surname><given-names>N.</given-names></name>
<name><surname>Gustavsson</surname><given-names>P.</given-names></name>
<name><surname>Andersson</surname><given-names>B.</given-names></name>
<name><surname>Pettersson</surname><given-names>M.</given-names></name>
</person-group> (<year>1999</year>) <article-title>The gene encoding ribosomal protein S19 is mutated in Diamond–Blackfan anaemia</article-title>. <source>Nat Genet</source> <volume>21</volume>: <fpage>169</fpage>–<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr42-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dupuis-Girod</surname><given-names>S.</given-names></name>
<name><surname>Medioni</surname><given-names>J.</given-names></name>
<name><surname>Haddad</surname><given-names>E.</given-names></name>
<name><surname>Quartier</surname><given-names>P.</given-names></name>
<name><surname>Cavazzana-Calvo</surname><given-names>M.</given-names></name>
<name><surname>Le Deist</surname><given-names>F.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Autoimmunity in Wiskott–Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients</article-title>. <source>Pediatrics</source> <volume>111</volume>: <fpage>e622</fpage>–<lpage>e627</lpage>.</citation>
</ref>
<ref id="bibr43-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dutt</surname><given-names>S.</given-names></name>
<name><surname>Narla</surname><given-names>A.</given-names></name>
<name><surname>Lin</surname><given-names>K.</given-names></name>
<name><surname>Mullally</surname><given-names>A.</given-names></name>
<name><surname>Abayasekara</surname><given-names>N.</given-names></name>
<name><surname>Megerdichian</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells</article-title>. <source>Blood</source> <volume>117</volume>: <fpage>2567</fpage>–<lpage>2576</lpage>.</citation>
</ref>
<ref id="bibr44-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ellis</surname><given-names>S.</given-names></name>
<name><surname>Gleizes</surname><given-names>P.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Diamond Blackfan anemia: ribosomal proteins going rogue</article-title>. <source>Semin Hematol</source> <volume>48</volume>: <fpage>89</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr45-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fanconi</surname><given-names>G.</given-names></name>
</person-group> (<year>1967</year>) <article-title>Familial constitutional panmyelocytopathy, Fanconi’s anemia (F.A.). I. Clinical aspects</article-title>. <source>Semin Hematol</source> <volume>4</volume>: <fpage>233</fpage>–<lpage>240</lpage>.</citation>
</ref>
<ref id="bibr46-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Friedman</surname><given-names>J.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Epidemiology of neurofibromatosis type 1</article-title>. <source>Am J Med Genet</source> <volume>89</volume>: <fpage>1</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr47-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Furuichi</surname><given-names>Y.</given-names></name>
<name><surname>Kitao</surname><given-names>S.</given-names></name>
<name><surname>Shimamoto</surname><given-names>A.</given-names></name>
<name><surname>Goto</surname><given-names>M.</given-names></name>
<name><surname>Miller</surname><given-names>R.</given-names></name>
<name><surname>Smithson</surname><given-names>W.</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Mutations in RECQL4 cause a subset of cases of Rothmund–Thomson syndrome</article-title>. <source>Nat Genet</source> <volume>22</volume>: <fpage>82</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr48-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gaidzik</surname><given-names>V.</given-names></name>
<name><surname>Bullinger</surname><given-names>L.</given-names></name>
<name><surname>Schlenk</surname><given-names>R.</given-names></name>
<name><surname>Zimmermann</surname><given-names>A.</given-names></name>
<name><surname>Rock</surname><given-names>J.</given-names></name>
<name><surname>Paschka</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML Study Group</article-title>. <source>J Clin Oncol</source> <volume>29</volume>: <fpage>1364</fpage>–<lpage>1372</lpage>.</citation>
</ref>
<ref id="bibr49-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gaitonde</surname><given-names>S.</given-names></name>
<name><surname>Boumendjel</surname><given-names>R.</given-names></name>
<name><surname>Angeles</surname><given-names>R.</given-names></name>
<name><surname>Rondelli</surname><given-names>D.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Familial childhood monosomy 7 and associated myelodysplasia</article-title>. <source>J Pediat Hematol Oncol</source> <volume>32</volume>: <fpage>e236</fpage>–<lpage>e237</lpage>.</citation>
</ref>
<ref id="bibr50-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gamis</surname><given-names>A.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Acute myeloid leukemia and Down Syndrome evolution of modern therapy? State of the art review</article-title>. <source>Pediatr Blood Cancer</source> <volume>44</volume>: <fpage>13</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr51-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gatti</surname><given-names>R.</given-names></name>
<name><surname>Becker-Catania</surname><given-names>S.</given-names></name>
<name><surname>Chun</surname><given-names>H.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Mitui</surname><given-names>M.</given-names></name>
<name><surname>Lai</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>The pathogenesis of ataxia-telangiectasia</article-title>. <source>Clinic Rev Allerg Immunol</source> <volume>20</volume>: <fpage>87</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr52-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geddis</surname><given-names>A.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Congenital amegakaryocytic thrombocytopenia</article-title>. <source>Pediatr Blood Cancer</source> <volume>57</volume>: <fpage>199</fpage>–<lpage>203</lpage>.</citation>
</ref>
<ref id="bibr53-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>German</surname><given-names>J.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Bloom’s syndrome</article-title>. <source>Dermatol Clin</source> <volume>13</volume>: <fpage>7</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr54-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>German</surname><given-names>J.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Bloom’s syndrome. XX. The first 100 cancers</article-title>. <source>Cancer Genet Cytogenet</source> <volume>93</volume>: <fpage>100</fpage>–<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr55-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Germeshausen</surname><given-names>M.</given-names></name>
<name><surname>Ballmaier</surname><given-names>M.</given-names></name>
<name><surname>Welte</surname><given-names>K.</given-names></name>
</person-group> (<year>2006</year>) <article-title>MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease</article-title>. <source>Hum Mutat</source> <volume>27</volume>: <fpage>296</fpage>–<lpage>296</lpage>.</citation>
</ref>
<ref id="bibr56-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldgar</surname><given-names>D.</given-names></name>
<name><surname>Easton</surname><given-names>D.</given-names></name>
<name><surname>Cannon-Albright</surname><given-names>L.</given-names></name>
<name><surname>Skolnick</surname><given-names>M.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands</article-title>. <source>J Natl Cancer I</source> <volume>86</volume>: <fpage>1600</fpage>–<lpage>1608</lpage>.</citation>
</ref>
<ref id="bibr57-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goto</surname><given-names>M.</given-names></name>
<name><surname>Miller</surname><given-names>R.</given-names></name>
<name><surname>Ishikawa</surname><given-names>Y.</given-names></name>
<name><surname>Sugano</surname><given-names>H.</given-names></name>
</person-group> (<year>1996</year>) <article-title>Excess of rare cancers in Werner syndrome (adult progeria)</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> <volume>5</volume>: <fpage>239</fpage>–<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr58-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gray</surname><given-names>M.</given-names></name>
<name><surname>Shen</surname><given-names>J.</given-names></name>
<name><surname>Kamath-Loeb</surname><given-names>A.</given-names></name>
<name><surname>Blank</surname><given-names>A.</given-names></name>
<name><surname>Sopher</surname><given-names>B.</given-names></name>
<name><surname>Martin</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>The Werner syndrome protein is a DNA helicase</article-title>. <source>Nat Genet</source> <volume>17</volume>: <fpage>100</fpage>–<lpage>103</lpage>.</citation>
</ref>
<ref id="bibr59-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gumy-Pause</surname><given-names>F.</given-names></name>
<name><surname>Wacker</surname><given-names>P.</given-names></name>
<name><surname>Sappino</surname><given-names>A.</given-names></name>
</person-group> (<year>2003</year>) <article-title>ATM gene and lymphoid malignancies</article-title>. <source>Leukemia</source> <volume>18</volume>: <fpage>238</fpage>–<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr60-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gunz</surname><given-names>F.</given-names></name>
<name><surname>Gunz</surname><given-names>J.</given-names></name>
<name><surname>Chapman</surname><given-names>C.</given-names></name>
<name><surname>Houston</surname><given-names>I.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Familial leukaemia: a study of 909 families</article-title>. <source>Scand J Haematol</source> <volume>15</volume>: <fpage>117</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr61-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gustavsson</surname><given-names>P.</given-names></name>
<name><surname>Willig</surname><given-names>T.</given-names></name>
<name><surname>Haeringen</surname><given-names>A.</given-names></name>
<name><surname>Tchernia</surname><given-names>G.</given-names></name>
<name><surname>Dianzani</surname><given-names>I.</given-names></name>
<name><surname>Donnér</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>Diamond–Blackfan anaemia: genetic homogeneity for a gene on chromosome 19q13 restricted to 1.8 Mb</article-title>. <source>Nat Genet</source> <volume>16</volume>: <fpage>368</fpage>–<lpage>371</lpage>.</citation>
</ref>
<ref id="bibr62-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hahn</surname><given-names>C.</given-names></name>
<name><surname>Chong</surname><given-names>C.</given-names></name>
<name><surname>Carmichael</surname><given-names>C.</given-names></name>
<name><surname>Wilkins</surname><given-names>E.</given-names></name>
<name><surname>Brautigan</surname><given-names>P.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia</article-title>. <source>Nat Genet</source> <volume>43</volume>: <fpage>1012</fpage>–<lpage>1017</lpage>.</citation>
</ref>
<ref id="bibr63-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hasle</surname><given-names>H.</given-names></name>
<name><surname>Clemmensen</surname><given-names>I.</given-names></name>
<name><surname>Mikkelsen</surname><given-names>M.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Risks of leukaemia and solid tumours in individuals with Down’s syndrome</article-title>. <source>Lancet</source> <volume>355</volume>: <fpage>165</fpage>–<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr64-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hertzberg</surname><given-names>L.</given-names></name>
<name><surname>Vendramini</surname><given-names>E.</given-names></name>
<name><surname>Ganmore</surname><given-names>I.</given-names></name>
<name><surname>Cazzaniga</surname><given-names>G.</given-names></name>
<name><surname>Schmitz</surname><given-names>M.</given-names></name>
<name><surname>Chalker</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group</article-title>. <source>Blood</source> <volume>115</volume>: <fpage>1006</fpage>–<lpage>1017</lpage>.</citation>
</ref>
<ref id="bibr65-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holmfeldt</surname><given-names>L.</given-names></name>
<name><surname>Wei</surname><given-names>L.</given-names></name>
<name><surname>Diaz-Flores</surname><given-names>E.</given-names></name>
<name><surname>Walsh</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Ding</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2013</year>) <article-title>The genomic landscape of hypodiploid acute lymphoblastic leukemia</article-title>. <source>Nat Genet</source> <volume>45</volume>: <fpage>242</fpage>–<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr66-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Horwitz</surname><given-names>M.</given-names></name>
</person-group> (<year>1997</year>) <article-title>The genetics of familial leukemia</article-title>. <source>Leukemia</source> <volume>11</volume>: <fpage>1347</fpage>–<lpage>1359</lpage>.</citation>
</ref>
<ref id="bibr67-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hsu</surname><given-names>A.</given-names></name>
<name><surname>Sampaio</surname><given-names>E.</given-names></name>
<name><surname>Khan</surname><given-names>J.</given-names></name>
<name><surname>Calvo</surname><given-names>K.</given-names></name>
<name><surname>Lemieux</surname><given-names>J.</given-names></name>
<name><surname>Patel</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome</article-title>. <source>Blood</source> <volume>118</volume>: <fpage>2653</fpage>–<lpage>2655</lpage>.</citation>
</ref>
<ref id="bibr68-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ihara</surname><given-names>K.</given-names></name>
<name><surname>Ishii</surname><given-names>E.</given-names></name>
<name><surname>Eguchi</surname><given-names>M.</given-names></name>
<name><surname>Takada</surname><given-names>H.</given-names></name>
<name><surname>Suminoe</surname><given-names>A.</given-names></name>
<name><surname>Good</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>96</volume>: <fpage>3132</fpage>–<lpage>3136</lpage>.</citation>
</ref>
<ref id="bibr69-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jin</surname><given-names>Y.</given-names></name>
<name><surname>Mazza</surname><given-names>C.</given-names></name>
<name><surname>Christie</surname><given-names>J.</given-names></name>
<name><surname>Giliani</surname><given-names>S.</given-names></name>
<name><surname>Fiorini</surname><given-names>M.</given-names></name>
<name><surname>Mella</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Mutations of the Wiskott–Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation</article-title>. <source>Blood</source> <volume>104</volume>: <fpage>4010</fpage>–<lpage>4019</lpage>.</citation>
</ref>
<ref id="bibr70-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jongmans</surname><given-names>M.</given-names></name>
<name><surname>Kuiper</surname><given-names>R.</given-names></name>
<name><surname>Carmichael</surname><given-names>C.</given-names></name>
<name><surname>Wilkins</surname><given-names>E.</given-names></name>
<name><surname>Dors</surname><given-names>N.</given-names></name>
<name><surname>Carmagnac</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome</article-title>. <source>Leukemia</source> <volume>24</volume>: <fpage>242</fpage>–<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr71-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jongmans</surname><given-names>M.</given-names></name>
<name><surname>van der Burgt</surname><given-names>I.</given-names></name>
<name><surname>Hoogerbrugge</surname><given-names>P.</given-names></name>
<name><surname>Noordam</surname><given-names>K.</given-names></name>
<name><surname>Yntema</surname><given-names>H.</given-names></name>
<name><surname>Nillesen</surname><given-names>W.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation</article-title>. <source>Eur J Hum Genet</source> <volume>19</volume>: <fpage>870</fpage>–<lpage>874</lpage>.</citation>
</ref>
<ref id="bibr72-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kardos</surname><given-names>G.</given-names></name>
<name><surname>Baumann</surname><given-names>I.</given-names></name>
<name><surname>Passmore</surname><given-names>S.</given-names></name>
<name><surname>Locatelli</surname><given-names>F.</given-names></name>
<name><surname>Hasle</surname><given-names>H.</given-names></name>
<name><surname>Schultz</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7</article-title>. <source>Blood</source> <volume>102</volume>: <fpage>1997</fpage>–<lpage>2003</lpage>.</citation>
</ref>
<ref id="bibr73-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kazenwadel</surname><given-names>J.</given-names></name>
<name><surname>Secker</surname><given-names>G.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Rosenfeld</surname><given-names>J.</given-names></name>
<name><surname>Wildin</surname><given-names>R.</given-names></name>
<name><surname>Cuellar-Rodriguez</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature</article-title>. <source>Blood</source> <volume>119</volume>: <fpage>1283</fpage>–<lpage>1291</lpage>.</citation>
</ref>
<ref id="bibr74-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Keane</surname><given-names>M.</given-names></name>
<name><surname>Ettenberg</surname><given-names>S.</given-names></name>
<name><surname>Nau</surname><given-names>M.</given-names></name>
<name><surname>Banerjee</surname><given-names>P.</given-names></name>
<name><surname>Cuello</surname><given-names>M.</given-names></name>
<name><surname>Penninger</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>cbl-3: a new mammalian cbl family protein</article-title>. <source>Oncogene</source> <volume>18</volume>: <fpage>3365</fpage>.</citation>
</ref>
<ref id="bibr75-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kee</surname><given-names>Y.</given-names></name>
<name><surname>D’Andrea</surname><given-names>A.D.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Molecular pathogenesis and clinical management of Fanconi anemia</article-title>. <source>J Clin Invest</source> <volume>122</volume>: <fpage>3799</fpage>–<lpage>3806</lpage>.</citation>
</ref>
<ref id="bibr76-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.W.</given-names></name>
<name><surname>Rai</surname><given-names>D.</given-names></name>
<name><surname>Aguiar</surname><given-names>R.C.T.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma</article-title>. <source>Clin Cancer Res</source> <volume>17</volume>: <fpage>6723</fpage>–<lpage>6732</lpage>.</citation>
</ref>
<ref id="bibr77-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kleihues</surname><given-names>P.</given-names></name>
<name><surname>Schäuble</surname><given-names>B.</given-names></name>
<name><surname>Hausen Zur</surname><given-names>A.</given-names></name>
<name><surname>Estève</surname><given-names>J.</given-names></name>
<name><surname>Ohgaki</surname><given-names>H.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Tumors associated with p53 germline mutations: a synopsis of 91 families</article-title>. <source>Am J Pathol</source> <volume>150</volume>: <fpage>1</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr78-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klein</surname><given-names>C.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Genetic defects in severe congenital neutropenia: emerging insights into life and death of human neutrophil granulocytes</article-title>. <source>Annu Rev Immunol</source> <volume>29</volume>: <fpage>399</fpage>–<lpage>413</lpage>.</citation>
</ref>
<ref id="bibr79-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klopocki</surname><given-names>E.</given-names></name>
<name><surname>Schulze</surname><given-names>H.</given-names></name>
<name><surname>Strauß</surname><given-names>G.</given-names></name>
<name><surname>Ott</surname><given-names>C.</given-names></name>
<name><surname>Hall</surname><given-names>J.</given-names></name>
<name><surname>Trotier</surname><given-names>F.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Complex inheritance pattern resembling autosomal recessive inheritance involving a microdeletion in thrombocytopenia–absent radius syndrome</article-title>. <source>Am J Med Genet</source> <volume>80</volume>: <fpage>232</fpage>–<lpage>240</lpage>.</citation>
</ref>
<ref id="bibr80-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Komatsuzaki</surname><given-names>S.</given-names></name>
<name><surname>Aoki</surname><given-names>Y.</given-names></name>
<name><surname>Niihori</surname><given-names>T.</given-names></name>
<name><surname>Okamoto</surname><given-names>N.</given-names></name>
<name><surname>Hennekam</surname><given-names>R.</given-names></name>
<name><surname>Hopman</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Mutation analysis of the SHOC2 gene in Noonan-like syndrome and in hematologic malignancies</article-title>. <source>J Hum Genet</source> <volume>55</volume>: <fpage>801</fpage>–<lpage>809</lpage>.</citation>
</ref>
<ref id="bibr81-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Korf</surname><given-names>B.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Malignancy in neurofibromatosis type 1</article-title>. <source>Oncologist</source> <volume>5</volume>: <fpage>477</fpage>–<lpage>485</lpage>.</citation>
</ref>
<ref id="bibr82-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kostmann</surname><given-names>R.</given-names></name>
</person-group> (<year>1956</year>) <article-title>Infantile genetic agranulocytosis; agranulocytosis infantilis hereditaria</article-title>. <source>Acta Paediatr Suppl</source> <volume>45</volume>: <fpage>1</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr83-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kratz</surname><given-names>C.</given-names></name>
</person-group> (<year>2005</year>) <article-title>The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease</article-title>. <source>Blood</source> <volume>106</volume>: <fpage>2183</fpage>–<lpage>2185</lpage>.</citation>
</ref>
<ref id="bibr84-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kratz</surname><given-names>C.</given-names></name>
<name><surname>Emerling</surname><given-names>B.</given-names></name>
<name><surname>Donovan</surname><given-names>S.</given-names></name>
<name><surname>Laig-Webster</surname><given-names>M.</given-names></name>
<name><surname>Taylor</surname><given-names>B.</given-names></name>
<name><surname>Thompson</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Candidate gene isolation and comparative analysis of a commonly deleted segment of 7q22 implicated in myeloid malignancies</article-title>. <source>Genomics</source> <volume>77</volume>: <fpage>171</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr85-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krüger</surname><given-names>L.</given-names></name>
<name><surname>Demuth</surname><given-names>I.</given-names></name>
<name><surname>Neitzel</surname><given-names>H.</given-names></name>
<name><surname>Varon</surname><given-names>R.</given-names></name>
<name><surname>Sperling</surname><given-names>K.</given-names></name>
<name><surname>Chrzanowska</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Cancer incidence in Nijmegen breakage syndrome is modulated by the amount of a variant NBS protein</article-title>. <source>Carcinogenesis</source> <volume>28</volume>: <fpage>107</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr86-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kutler</surname><given-names>D.</given-names></name>
</person-group> (<year>2003</year>) <article-title>A 20-year perspective on the International Fanconi Anemia Registry (IFAR)</article-title>. <source>Blood</source> <volume>101</volume>: <fpage>1249</fpage>–<lpage>1256</lpage>.</citation>
</ref>
<ref id="bibr87-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Paull</surname><given-names>T.</given-names></name>
</person-group> (<year>2005</year>) <article-title>ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex</article-title>. <source>Science</source> <volume>308</volume>: <fpage>551</fpage>–<lpage>554</lpage>.</citation>
</ref>
<ref id="bibr88-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levran</surname><given-names>O.</given-names></name>
<name><surname>Attwooll</surname><given-names>C.</given-names></name>
<name><surname>Henry</surname><given-names>R.</given-names></name>
<name><surname>Milton</surname><given-names>K.</given-names></name>
<name><surname>Neveling</surname><given-names>K.</given-names></name>
<name><surname>Rio</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia</article-title>. <source>Nat Genet</source> <volume>37</volume>: <fpage>931</fpage>–<lpage>933</lpage>.</citation>
</ref>
<ref id="bibr89-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>F.</given-names></name>
</person-group> (<year>1969</year>) <article-title>Soft-tissue sarcomas, breast cancer, and other neoplasms : a familial syndrome?</article-title> <source>Ann Intern Med</source> <volume>71</volume>: <fpage>747</fpage>–<lpage>752</lpage>.</citation>
</ref>
<ref id="bibr90-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lipton</surname><given-names>J.</given-names></name>
<name><surname>Atsidaftos</surname><given-names>E.</given-names></name>
<name><surname>Zyskind</surname><given-names>I.</given-names></name>
<name><surname>Vlachos</surname><given-names>A.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry</article-title>. <source>Pediatr Blood Cancer</source> <volume>46</volume>: <fpage>558</fpage>–<lpage>564</lpage>.</citation>
</ref>
<ref id="bibr91-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lipton</surname><given-names>J.</given-names></name>
<name><surname>Federman</surname><given-names>N.</given-names></name>
<name><surname>Khabbaze</surname><given-names>Y.</given-names></name>
<name><surname>Schwartz</surname><given-names>C.</given-names></name>
<name><surname>Hilliard</surname><given-names>L.</given-names></name>
<name><surname>Clark</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Osteogenic sarcoma associated with Diamond–Blackfan anemia: a report from the Diamond–Blackfan Anemia Registry</article-title>. <source>J Pediat Hematol Oncol</source> <volume>23</volume>: <fpage>39</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr92-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Loh</surname><given-names>M.</given-names></name>
<name><surname>Vattikuti</surname><given-names>S.</given-names></name>
<name><surname>Schubbert</surname><given-names>S.</given-names></name>
<name><surname>Reynolds</surname><given-names>M.</given-names></name>
<name><surname>Carlson</surname><given-names>E.</given-names></name>
<name><surname>Lieuw</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis</article-title>. <source>Blood</source> <volume>103</volume>: <fpage>2325</fpage>–<lpage>2331</lpage>.</citation>
</ref>
<ref id="bibr93-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lynch</surname><given-names>H.</given-names></name>
<name><surname>Boland</surname><given-names>C.</given-names></name>
<name><surname>Gong</surname><given-names>G.</given-names></name>
<name><surname>Shaw</surname><given-names>T.</given-names></name>
<name><surname>Lynch</surname><given-names>P.</given-names></name>
<name><surname>Fodde</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications</article-title>. <source>Eur J Hum Genet</source> <volume>14</volume>: <fpage>390</fpage>–<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr94-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malinge</surname><given-names>S.</given-names></name>
<name><surname>Izraeli</surname><given-names>S.</given-names></name>
<name><surname>Crispino</surname><given-names>J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome</article-title>. <source>Blood</source> <volume>113</volume>: <fpage>2619</fpage>–<lpage>2628</lpage>.</citation>
</ref>
<ref id="bibr95-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malkin</surname><given-names>D.</given-names></name>
<name><surname>Li</surname><given-names>F.</given-names></name>
<name><surname>Strong</surname><given-names>L.</given-names></name>
<name><surname>Fraumeni</surname><given-names>J.</given-names></name>
<name><surname>Nelson</surname><given-names>C.</given-names></name>
<name><surname>Kim</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>1990</year>) <article-title>Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms</article-title>. <source>Science</source> <volume>250</volume>: <fpage>1233</fpage>–<lpage>1238</lpage>.</citation>
</ref>
<ref id="bibr96-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martinelli</surname><given-names>S.</given-names></name>
<name><surname>De Luca</surname><given-names>A.</given-names></name>
<name><surname>Stellacci</surname><given-names>E.</given-names></name>
<name><surname>Rossi</surname><given-names>C.</given-names></name>
<name><surname>Checquolo</surname><given-names>S.</given-names></name>
<name><surname>Lepri</surname><given-names>F.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype</article-title>. <source>Am J Med Genet</source> <volume>87</volume>: <fpage>250</fpage>–<lpage>257</lpage>.</citation>
</ref>
<ref id="bibr97-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Massey</surname><given-names>G.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Transient leukemia in newborns with Down syndrome</article-title>. <source>Pediatr Blood Cancer</source> <volume>44</volume>: <fpage>29</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr98-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McLean</surname><given-names>T.</given-names></name>
<name><surname>Ringold</surname><given-names>S.</given-names></name>
<name><surname>Neuberg</surname><given-names>D.</given-names></name>
<name><surname>Stegmaier</surname><given-names>K.</given-names></name>
<name><surname>Tantravahi</surname><given-names>R.</given-names></name>
<name><surname>Ritz</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>1996</year>) <article-title>TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia</article-title>. <source>Blood</source> <volume>88</volume>: <fpage>4252</fpage>–<lpage>4258</lpage>.</citation>
</ref>
<ref id="bibr99-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Minelli</surname><given-names>A.</given-names></name>
<name><surname>Maserati</surname><given-names>E.</given-names></name>
<name><surname>Giudici</surname><given-names>G.</given-names></name>
<name><surname>Tosi</surname><given-names>S.</given-names></name>
<name><surname>Olivieri</surname><given-names>C.</given-names></name>
<name><surname>Bonvini</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Familial partial monosomy 7 and myelodysplasia: different parental origin of the monosomy 7 suggests action of a mutator gene</article-title>. <source>Cancer Genet Cytogenet</source> <volume>124</volume>: <fpage>147</fpage>–<lpage>151</lpage>.</citation>
</ref>
<ref id="bibr100-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morrell</surname><given-names>D.</given-names></name>
<name><surname>Cromartie</surname><given-names>E.</given-names></name>
<name><surname>Swift</surname><given-names>M.</given-names></name>
</person-group> (<year>1986</year>) <article-title>Mortality and cancer incidence in 263 patients with ataxia-telangiectasia</article-title>. <source>J Natl Cancer I</source> <volume>77</volume>: <fpage>89</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr101-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mueller</surname><given-names>B.</given-names></name>
<name><surname>Pizzo</surname><given-names>P.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Cancer in children with primary or secondary immunodeficiencies</article-title>. <source>J Pediatr</source> <volume>126</volume>: <fpage>1</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr102-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mullighan</surname><given-names>C.</given-names></name>
<name><surname>Collins-Underwood</surname><given-names>J.</given-names></name>
<name><surname>Phillips</surname><given-names>L.</given-names></name>
<name><surname>Loudin</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Rearrangement of CRLF2 in B-progenitor–and Down syndrome–associated acute lymphoblastic leukemia</article-title>. <source>Nat Genet</source> <volume>41</volume>: <fpage>1243</fpage>–<lpage>1246</lpage>.</citation>
</ref>
<ref id="bibr103-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Myers</surname><given-names>K.</given-names></name>
<name><surname>Davies</surname><given-names>S.</given-names></name>
<name><surname>Shimamura</surname><given-names>A.</given-names></name>
</person-group> (<year>2013</year>) <article-title>Clinical and molecular pathophysiology of Shwachman–Diamond syndrome: an update</article-title>. <source>Hematol Oncol Clin North Am</source> <volume>27</volume>: <fpage>117</fpage>–<lpage>128</lpage>.</citation>
</ref>
<ref id="bibr104-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Narla</surname><given-names>A.</given-names></name>
<name><surname>Ebert</surname><given-names>B.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Ribosomopathies: human disorders of ribosome dysfunction</article-title>. <source>Blood</source> <volume>115</volume>: <fpage>3196</fpage>–<lpage>3205</lpage>.</citation>
</ref>
<ref id="bibr105-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Niemeyer</surname><given-names>C.</given-names></name>
<name><surname>Kang</surname><given-names>M.</given-names></name>
<name><surname>Shin</surname><given-names>D.</given-names></name>
<name><surname>Furlan</surname><given-names>I.</given-names></name>
<name><surname>Erlacher</surname><given-names>M.</given-names></name>
<name><surname>Bunin</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia</article-title>. <source>Nat Genet</source> <volume>42</volume>: <fpage>794</fpage>–<lpage>800</lpage>.</citation>
</ref>
<ref id="bibr106-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nigro</surname><given-names>J.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
<name><surname>Preisinger</surname><given-names>A.</given-names></name>
<name><surname>Jessup</surname><given-names>J.</given-names></name>
<name><surname>Hosteller</surname><given-names>R.</given-names></name>
<name><surname>Cleary</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>1989</year>) <article-title>Mutations in the p53 gene occur in diverse human tumour types</article-title>. <source>Nature</source> <volume>342</volume>: <fpage>705</fpage>–<lpage>708</lpage>.</citation>
</ref>
<ref id="bibr107-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Noonan</surname><given-names>J.</given-names></name>
</person-group> (<year>1968</year>) <article-title>Hypertelorism with Turner phenotype: a new syndrome with associated congenital heart disease</article-title>. <source>Arch Pediatr Adolesc Med</source> <volume>116</volume>: <fpage>373</fpage>–<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr108-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ochs</surname><given-names>H.</given-names></name>
<name><surname>Thrasher</surname><given-names>A.</given-names></name>
</person-group> (<year>2006</year>) <article-title>The Wiskott–Aldrich syndrome</article-title>. <source>J Allergy Clin Immunol</source> <volume>117</volume>: <fpage>725</fpage>–<lpage>738</lpage>.</citation>
</ref>
<ref id="bibr109-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Orsi</surname><given-names>L.</given-names></name>
<name><surname>Rudant</surname><given-names>J.</given-names></name>
<name><surname>Bonaventure</surname><given-names>A.</given-names></name>
<name><surname>Goujon-Bellec</surname><given-names>S.</given-names></name>
<name><surname>Corda</surname><given-names>E.</given-names></name>
<name><surname>Evans</surname><given-names>T.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Genetic polymorphisms and childhood acute lymphoblastic leukemia: GWAS of the ESCALE study (SFCE)</article-title>. <source>Leukemia</source> <volume>26</volume>: <fpage>2561</fpage>–<lpage>2564</lpage>.</citation>
</ref>
<ref id="bibr110-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Osato</surname><given-names>M.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia</article-title>. <source>Oncogene</source> <volume>23</volume>: <fpage>4284</fpage>–<lpage>4296</lpage>.</citation>
</ref>
<ref id="bibr111-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ostergaard</surname><given-names>P.</given-names></name>
<name><surname>Simpson</surname><given-names>M.</given-names></name>
<name><surname>Connell</surname><given-names>F.</given-names></name>
<name><surname>Steward</surname><given-names>C.</given-names></name>
<name><surname>Brice</surname><given-names>G.</given-names></name>
<name><surname>Woollard</surname><given-names>W.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome)</article-title>. <source>Nat Genet</source> <volume>43</volume>: <fpage>929</fpage>–<lpage>931</lpage>.</citation>
</ref>
<ref id="bibr112-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Owen</surname><given-names>C.</given-names></name>
<name><surname>Barnett</surname><given-names>M.</given-names></name>
<name><surname>Fitzgibbon</surname><given-names>J.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Familial myelodysplasia and acute myeloid leukaemia - a review</article-title>. <source>Br J Haematol</source> <volume>140</volume>: <fpage>123</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr113-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Owen</surname><given-names>C.</given-names></name>
<name><surname>Toze</surname><given-names>C.</given-names></name>
<name><surname>Koochin</surname><given-names>A.</given-names></name>
<name><surname>Forrest</surname><given-names>D.</given-names></name>
<name><surname>Smith</surname><given-names>C.</given-names></name>
<name><surname>Stevens</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy</article-title>. <source>Blood</source> <volume>112</volume>: <fpage>4639</fpage>–<lpage>4645</lpage>.</citation>
</ref>
<ref id="bibr114-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pabst</surname><given-names>T.</given-names></name>
<name><surname>Eyholzer</surname><given-names>M.</given-names></name>
<name><surname>Haefliger</surname><given-names>S.</given-names></name>
<name><surname>Schardt</surname><given-names>J.</given-names></name>
<name><surname>Mueller</surname><given-names>B.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia</article-title>. <source>J Clin Oncol</source> <volume>26</volume>: <fpage>5088</fpage>–<lpage>5093</lpage>.</citation>
</ref>
<ref id="bibr115-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pabst</surname><given-names>T.</given-names></name>
<name><surname>Mueller</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Radomska</surname><given-names>H.</given-names></name>
<name><surname>Narravula</surname><given-names>S.</given-names></name>
<name><surname>Schnittger</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia</article-title>. <source>Nat Genet</source> <volume>27</volume>: <fpage>263</fpage>–<lpage>270</lpage>.</citation>
</ref>
<ref id="bibr116-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Page</surname><given-names>A.</given-names></name>
<name><surname>Hansen</surname><given-names>A.</given-names></name>
<name><surname>Good</surname><given-names>R.</given-names></name>
</person-group> (<year>1963</year>) <article-title>Occurrence of leukemia and lymphoma in patients with agammaglobulinemia</article-title>. <source>Blood</source> <volume>21</volume>: <fpage>197</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr117-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parikh</surname><given-names>S.</given-names></name>
<name><surname>Bessler</surname><given-names>M.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Recent insights into inherited bone marrow failure syndromes</article-title>. <source>Curr Opin Pediatr</source> <volume>24</volume>: <fpage>23</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr118-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pasquet</surname><given-names>M.</given-names></name>
<name><surname>Bellanné-Chantelot</surname><given-names>C.</given-names></name>
<name><surname>Tavitian</surname><given-names>S.</given-names></name>
<name><surname>Prade</surname><given-names>N.</given-names></name>
<name><surname>Beaupain</surname><given-names>B.</given-names></name>
<name><surname>LaRochelle</surname><given-names>O.</given-names></name><etal/>
</person-group>. (<year>2013</year>) <article-title>High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia</article-title>. <source>Blood</source> <volume>121</volume>: <fpage>822</fpage>–<lpage>829</lpage>.</citation>
</ref>
<ref id="bibr119-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pause</surname><given-names>F.</given-names></name>
<name><surname>Wacker</surname><given-names>P.</given-names></name>
<name><surname>Maillet</surname><given-names>P.</given-names></name>
<name><surname>Betts</surname><given-names>D.</given-names></name>
<name><surname>Sappino</surname><given-names>A.</given-names></name>
</person-group> (<year>2003</year>) <article-title>ATM gene alterations in childhood acute lymphoblastic leukemias</article-title>. <source>Hum Mutat</source> <volume>21</volume>: <fpage>554</fpage>.</citation>
</ref>
<ref id="bibr120-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peltomaki</surname><given-names>P.</given-names></name>
<name><surname>Vasen</surname><given-names>H.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Mutations associated with HNPCC predisposition – update of ICG-HNPCC/INSiGHT mutation database</article-title>. <source>Dis Markers</source> <volume>20</volume>: <fpage>269</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr121-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pollard</surname><given-names>J.</given-names></name>
<name><surname>Gatti</surname><given-names>R.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Clinical radiation sensitivity with DNA repair disorders: an overview</article-title>. <source>Int J Radiat Oncol</source> <volume>74</volume>: <fpage>1323</fpage>–<lpage>1331</lpage>.</citation>
</ref>
<ref id="bibr122-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Powell</surname><given-names>B.</given-names></name>
<name><surname>Jiang</surname><given-names>L.</given-names></name>
<name><surname>Muzny</surname><given-names>D.</given-names></name>
<name><surname>Treviño</surname><given-names>L.</given-names></name>
<name><surname>Dreyer</surname><given-names>Z.</given-names></name>
<name><surname>Strong</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing</article-title>. <source>Pediatr Blood Cancer</source> <volume>60</volume>: <fpage>E1</fpage>–<lpage>E3</lpage>.</citation>
</ref>
<ref id="bibr123-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Preudhomme</surname><given-names>C.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)</article-title>. <source>Blood</source> <volume>100</volume>: <fpage>2717</fpage>–<lpage>2723</lpage>.</citation>
</ref>
<ref id="bibr124-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rasmussen</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>W.</given-names></name>
<name><surname>Friedman</surname><given-names>J.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Mortality in neurofibromatosis 1: an analysis using U.S. death certificates</article-title>. <source>Am J Hum Genet</source> <volume>68</volume>: <fpage>1110</fpage>–<lpage>1118</lpage>.</citation>
</ref>
<ref id="bibr125-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ravindranath</surname><given-names>Y.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Down syndrome and leukemia: new insights into the epidemiology, pathogenesis, and treatment</article-title>. <source>Pediatr Blood Cancer</source> <volume>44</volume>: <fpage>1</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr126-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rawlings</surname><given-names>D.</given-names></name>
<name><surname>Witte</surname><given-names>O.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Bruton’s tyrosine kinase is a key regulator in B-cell development</article-title>. <source>Immunol Rev</source> <volume>138</volume>: <fpage>105</fpage>–<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr127-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Razzaque</surname><given-names>M.</given-names></name>
<name><surname>Nishizawa</surname><given-names>T.</given-names></name>
<name><surname>Komoike</surname><given-names>Y.</given-names></name>
<name><surname>Yagi</surname><given-names>H.</given-names></name>
<name><surname>Furutani</surname><given-names>M.</given-names></name>
<name><surname>Amo</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Germline gain-of-function mutations in RAF1 cause Noonan syndrome</article-title>. <source>Nat Genet</source> <volume>39</volume>: <fpage>1013</fpage>–<lpage>1017</lpage>.</citation>
</ref>
<ref id="bibr128-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reid</surname><given-names>S.</given-names></name>
<name><surname>Schindler</surname><given-names>D.</given-names></name>
<name><surname>Hanenberg</surname><given-names>H.</given-names></name>
<name><surname>Barker</surname><given-names>K.</given-names></name>
<name><surname>Hanks</surname><given-names>S.</given-names></name>
<name><surname>Kalb</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer</article-title>. <source>Nat Genet</source> <volume>39</volume>: <fpage>162</fpage>–<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr129-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Renneville</surname><given-names>A.</given-names></name>
<name><surname>Mialou</surname><given-names>V.</given-names></name>
<name><surname>Philippe</surname><given-names>N.</given-names></name>
<name><surname>Kagialis-Girard</surname><given-names>S.</given-names></name>
<name><surname>Biggio</surname><given-names>V.</given-names></name>
<name><surname>Zabot</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation</article-title>. <source>Leukemia</source> <volume>23</volume>: <fpage>804</fpage>–<lpage>806</lpage>.</citation>
</ref>
<ref id="bibr130-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rey</surname><given-names>M.</given-names></name>
<name><surname>Duffy</surname><given-names>S.</given-names></name>
<name><surname>Brown</surname><given-names>J.</given-names></name>
<name><surname>Kennedy</surname><given-names>J.</given-names></name>
<name><surname>Dick</surname><given-names>J.</given-names></name>
<name><surname>Dror</surname><given-names>Y.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Enhanced alternative splicing of the FLVCR1 gene in Diamond Blackfan anemia disrupts FLVCR1 expression and function that are critical for erythropoiesis</article-title>. <source>Haematologica</source> <volume>93</volume>: <fpage>1617</fpage>–<lpage>1626</lpage>.</citation>
</ref>
<ref id="bibr131-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ricciardone</surname><given-names>M.</given-names></name>
<name><surname>Özçelik</surname><given-names>T.</given-names></name>
<name><surname>Cevher</surname><given-names>B.</given-names></name>
<name><surname>Özdağ</surname><given-names>H.</given-names></name>
<name><surname>Tuncer</surname><given-names>M.</given-names></name>
<name><surname>Gürgey</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1</article-title>. <source>Cancer Res</source> <volume>59</volume>: <fpage>290</fpage>–<lpage>293</lpage>.</citation>
</ref>
<ref id="bibr132-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roa</surname><given-names>B.</given-names></name>
<name><surname>Savino</surname><given-names>C.</given-names></name>
<name><surname>Richards</surname><given-names>C.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Ashkenazi Jewish population frequency of the Bloom syndrome gene 2281Δ6ins7 mutation</article-title>. <source>Genet Test</source> <volume>3</volume>: <fpage>219</fpage>–<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr133-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>A.</given-names></name>
<name><surname>Allanson</surname><given-names>J.</given-names></name>
<name><surname>Tartaglia</surname><given-names>M.</given-names></name>
<name><surname>Gelb</surname><given-names>B.</given-names></name>
</person-group> (<year>2013</year>) <article-title>Noonan syndrome</article-title>. <source>Lancet</source> <volume>381</volume>: <fpage>333</fpage>–<lpage>342</lpage>.</citation>
</ref>
<ref id="bibr134-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>A.</given-names></name>
<name><surname>Araki</surname><given-names>T.</given-names></name>
<name><surname>Swanson</surname><given-names>K.</given-names></name>
<name><surname>Montgomery</surname><given-names>K.</given-names></name>
<name><surname>Schiripo</surname><given-names>T.</given-names></name>
<name><surname>Joshi</surname><given-names>V.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Germline gain-of-function mutations in SOS1 cause Noonan syndrome</article-title>. <source>Nat Genet</source> <volume>39</volume>: <fpage>70</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr135-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rodriguez-Viciana</surname><given-names>P.</given-names></name>
<name><surname>Tetsu</surname><given-names>O.</given-names></name>
<name><surname>Tidyman</surname><given-names>W.</given-names></name>
<name><surname>Estep</surname><given-names>A.</given-names></name>
<name><surname>Conger</surname><given-names>B.</given-names></name>
<name><surname>Cruz</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome</article-title>. <source>Science</source> <volume>311</volume>: <fpage>1287</fpage>–<lpage>1290</lpage>.</citation>
</ref>
<ref id="bibr136-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenberg</surname><given-names>P.</given-names></name>
<name><surname>Zeidler</surname><given-names>C.</given-names></name>
<name><surname>Bolyard</surname><given-names>A.</given-names></name>
<name><surname>Alter</surname><given-names>B.</given-names></name>
<name><surname>Bonilla</surname><given-names>M.</given-names></name>
<name><surname>Boxer</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy</article-title>. <source>Br J Haematol</source> <volume>150</volume>: <fpage>196</fpage>–<lpage>199</lpage>.</citation>
</ref>
<ref id="bibr137-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanada</surname><given-names>M.</given-names></name>
<name><surname>Suzuki</surname><given-names>T.</given-names></name>
<name><surname>Shih</surname><given-names>L.</given-names></name>
<name><surname>Otsu</surname><given-names>M.</given-names></name>
<name><surname>Kato</surname><given-names>M.</given-names></name>
<name><surname>Yamazaki</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms</article-title>. <source>Nature</source> <volume>460</volume>: <fpage>904</fpage>–<lpage>908</lpage>.</citation>
</ref>
<ref id="bibr138-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sankaran</surname><given-names>V.</given-names></name>
<name><surname>Ghazvinian</surname><given-names>R.</given-names></name>
<name><surname>Do</surname><given-names>R.</given-names></name>
<name><surname>Thiru</surname><given-names>P.</given-names></name>
<name><surname>Vergilio</surname><given-names>J.</given-names></name>
<name><surname>Beggs</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Exome sequencing identifies GATA1 mutations resulting in Diamond–Blackfan anemia</article-title>. <source>J Clin Invest</source> <volume>122</volume>: <fpage>2439</fpage>–<lpage>2443</lpage>.</citation>
</ref>
<ref id="bibr139-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sarkozy</surname><given-names>A.</given-names></name>
<name><surname>Carta</surname><given-names>C.</given-names></name>
<name><surname>Moretti</surname><given-names>S.</given-names></name>
<name><surname>Zampino</surname><given-names>G.</given-names></name>
<name><surname>Digilio</surname><given-names>M.</given-names></name>
<name><surname>Pantaleoni</surname><given-names>F.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum</article-title>. <source>Hum Mutat</source> <volume>30</volume>: <fpage>695</fpage>–<lpage>702</lpage>.</citation>
</ref>
<ref id="bibr140-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Savage</surname><given-names>S.</given-names></name>
<name><surname>Bertuch</surname><given-names>A.</given-names></name>
</person-group> (<year>2010</year>) <article-title>The genetics and clinical manifestations of telomere biology disorders</article-title>. <source>Genet Med</source> <volume>12</volume>: <fpage>753</fpage>–<lpage>764</lpage>.</citation>
</ref>
<ref id="bibr141-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmidt</surname><given-names>M.</given-names></name>
<name><surname>Dikic</surname><given-names>I.</given-names></name>
</person-group> (<year>2005</year>) <article-title>The Cbl interactome and its functions</article-title>. <source>Nat Rev Mol Cell Biol</source> <volume>6</volume>: <fpage>907</fpage>–<lpage>918</lpage>.</citation>
</ref>
<ref id="bibr142-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schubbert</surname><given-names>S.</given-names></name>
<name><surname>Zenker</surname><given-names>M.</given-names></name>
<name><surname>Rowe</surname><given-names>S.</given-names></name>
<name><surname>Böll</surname><given-names>S.</given-names></name>
<name><surname>Klein</surname><given-names>C.</given-names></name>
<name><surname>Bollag</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Germline KRAS mutations cause Noonan syndrome</article-title>. <source>Nat Genet</source> <volume>38</volume>: <fpage>331</fpage>–<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr143-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sellick</surname><given-names>G.</given-names></name>
<name><surname>Spendlove</surname><given-names>H.</given-names></name>
<name><surname>Catovsky</surname><given-names>D.</given-names></name>
<name><surname>Pritchard-Jones</surname><given-names>K.</given-names></name>
<name><surname>Houlston</surname><given-names>R.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia</article-title>. <source>Leukemia</source> <volume>19</volume>: <fpage>1276</fpage>–<lpage>1278</lpage>.</citation>
</ref>
<ref id="bibr144-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shannon</surname><given-names>K.</given-names></name>
<name><surname>Turhan</surname><given-names>A.</given-names></name>
<name><surname>Rogers</surname><given-names>P.</given-names></name>
<name><surname>Kan</surname><given-names>Y.</given-names></name>
</person-group> (<year>1992</year>) <article-title>Evidence implicating heterozygous deletion of chromosome 7 in the pathogenesis of familial leukemia associated with monosomy 7</article-title>. <source>Genomics</source> <volume>14</volume>: <fpage>121</fpage>–<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr145-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shapiro</surname><given-names>R.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Malignancies in the setting of primary immunodeficiency: implications for hematologists/oncologists</article-title>. <source>Am J Hematol</source> <volume>86</volume>: <fpage>48</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr146-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sherborne</surname><given-names>A.</given-names></name>
<name><surname>Hosking</surname><given-names>F.</given-names></name>
<name><surname>Prasad</surname><given-names>R.</given-names></name>
<name><surname>Kumar</surname><given-names>R.</given-names></name>
<name><surname>Koehler</surname><given-names>R.</given-names></name>
<name><surname>Vijayakrishnan</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Variation in CDKN2A at 9p21. 3 influences childhood acute lymphoblastic leukemia risk</article-title>. <source>Nat Genet</source> <volume>42</volume>: <fpage>492</fpage>–<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr147-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Side</surname><given-names>L.</given-names></name>
<name><surname>Emanuel</surname><given-names>P.</given-names></name>
<name><surname>Taylor</surname><given-names>B.</given-names></name>
<name><surname>Franklin</surname><given-names>J.</given-names></name>
<name><surname>Thompson</surname><given-names>P.</given-names></name>
<name><surname>Castleberry</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1</article-title>. <source>Blood</source> <volume>92</volume>: <fpage>267</fpage>–<lpage>272</lpage>.</citation>
</ref>
<ref id="bibr148-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Siitonen</surname><given-names>H.</given-names></name>
<name><surname>Sotkasiira</surname><given-names>J.</given-names></name>
<name><surname>Biervliet</surname><given-names>M.</given-names></name>
<name><surname>Benmansour</surname><given-names>A.</given-names></name>
<name><surname>Capri</surname><given-names>Y.</given-names></name>
<name><surname>Cormier-Daire</surname><given-names>V.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>The mutation spectrum in RECQL4 diseases</article-title>. <source>Eur J Hum Genet</source> <volume>17</volume>: <fpage>151</fpage>–<lpage>158</lpage>.</citation>
</ref>
<ref id="bibr149-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>M.</given-names></name>
<name><surname>Cavenagh</surname><given-names>J.</given-names></name>
<name><surname>Lister</surname><given-names>T.</given-names></name>
<name><surname>Fitzgibbon</surname><given-names>J.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Mutation of CEBPA in familial acute myeloid leukemia</article-title>. <source>N Engl J Med</source> <volume>351</volume>: <fpage>2403</fpage>–<lpage>2407</lpage>.</citation>
</ref>
<ref id="bibr150-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Song</surname><given-names>W.</given-names></name>
<name><surname>Sullivan</surname><given-names>M.</given-names></name>
<name><surname>Legare</surname><given-names>R.</given-names></name>
<name><surname>Hutchings</surname><given-names>S.</given-names></name>
<name><surname>Tan</surname><given-names>X.</given-names></name>
<name><surname>Kufrin</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia</article-title>. <source>Nat Genet</source> <volume>23</volume>: <fpage>166</fpage>–<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr151-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stiller</surname><given-names>C.</given-names></name>
<name><surname>Chessells</surname><given-names>J.</given-names></name>
<name><surname>Fitchett</surname><given-names>M.</given-names></name>
</person-group> (<year>1994</year>) <article-title>Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study</article-title>. <source>Br J Cancer</source> <volume>70</volume>: <fpage>969</fpage>–<lpage>972</lpage>.</citation>
</ref>
<ref id="bibr152-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Straughen</surname><given-names>J.</given-names></name>
<name><surname>Ciocci</surname><given-names>S.</given-names></name>
<name><surname>Ye</surname><given-names>T.</given-names></name>
<name><surname>Lennon</surname><given-names>D.</given-names></name>
<name><surname>Proytcheva</surname><given-names>M.</given-names></name>
<name><surname>Alhadeff</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>1996</year>) <article-title>Physical mapping of the Bloom syndrome region by the identification of YAC and P1 clones from human chromosome 15 band q26. 1</article-title>. <source>Genomics</source> <volume>35</volume>: <fpage>118</fpage>–<lpage>128</lpage>.</citation>
</ref>
<ref id="bibr153-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stray-Pedersen</surname><given-names>A.</given-names></name>
<name><surname>Borresen-Dale</surname><given-names>A.</given-names></name>
<name><surname>Paus</surname><given-names>E.</given-names></name>
<name><surname>Lindman</surname><given-names>C.</given-names></name>
<name><surname>Burgers</surname><given-names>T.</given-names></name>
<name><surname>Abrahamsen</surname><given-names>T.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Alpha fetoprotein is increasing with age in ataxia–telangiectasia</article-title>. <source>Eur J Paediatr Neurol</source> <volume>11</volume>: <fpage>375</fpage>–<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr154-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sullivan</surname><given-names>K.</given-names></name>
<name><surname>Mullen</surname><given-names>C.</given-names></name>
<name><surname>Blaese</surname><given-names>R.</given-names></name>
<name><surname>Winkelstein</surname><given-names>J.</given-names></name>
</person-group> (<year>1994</year>) <article-title>A multiinstitutional survey of the Wiskott–Aldrich syndrome</article-title>. <source>J Pediatr</source> <volume>125</volume>: <fpage>876</fpage>–<lpage>885</lpage>.</citation>
</ref>
<ref id="bibr155-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tartaglia</surname><given-names>M.</given-names></name>
<name><surname>Martinelli</surname><given-names>S.</given-names></name>
<name><surname>Stella</surname><given-names>L.</given-names></name>
<name><surname>Bocchinfuso</surname><given-names>G.</given-names></name>
<name><surname>Flex</surname><given-names>E.</given-names></name>
<name><surname>Cordeddu</surname><given-names>V.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease</article-title>. <source>Am J Med Genet</source> <volume>78</volume>: <fpage>279</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr156-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tartaglia</surname><given-names>M.</given-names></name>
<name><surname>Mehler</surname><given-names>E.</given-names></name>
<name><surname>Goldberg</surname><given-names>R.</given-names></name>
<name><surname>Zampino</surname><given-names>G.</given-names></name>
<name><surname>Brunner</surname><given-names>H.</given-names></name>
<name><surname>Kremer</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome</article-title>. <source>Nat Genet</source> <volume>29</volume>: <fpage>465</fpage>–<lpage>468</lpage>.</citation>
</ref>
<ref id="bibr157-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tartaglia</surname><given-names>M.</given-names></name>
<name><surname>Niemeyer</surname><given-names>C.</given-names></name>
<name><surname>Fragale</surname><given-names>A.</given-names></name>
<name><surname>Song</surname><given-names>X.</given-names></name>
<name><surname>Buechner</surname><given-names>J.</given-names></name>
<name><surname>Jung</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia</article-title>. <source>Nat Genet</source> <volume>34</volume>: <fpage>148</fpage>–<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr158-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taub</surname><given-names>J.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome</article-title>. <source>Blood</source> <volume>104</volume>: <fpage>1588</fpage>–<lpage>1589</lpage>.</citation>
</ref>
<ref id="bibr159-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>D.</given-names></name>
<name><surname>Duedal</surname><given-names>S.</given-names></name>
<name><surname>Kirner</surname><given-names>J.</given-names></name>
<name><surname>McGuffog</surname><given-names>L.</given-names></name>
<name><surname>Last</surname><given-names>J.</given-names></name>
<name><surname>Reiman</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Cancer risks and mortality in heterozygous ATM mutation carriers</article-title>. <source>J Natl Cancer I</source> <volume>97</volume>: <fpage>813</fpage>–<lpage>822</lpage>.</citation>
</ref>
<ref id="bibr160-2040620713498161">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Tidyman</surname><given-names>W.</given-names></name>
<name><surname>Rauen</surname><given-names>K.</given-names></name>
</person-group> (<year>2012</year>) <source>The RASopathies: Syndromes of Ras/MAPK Pathway Dysregulation</source>. <publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer</publisher-name>.</citation>
</ref>
<ref id="bibr161-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Treviño</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>W.</given-names></name>
<name><surname>French</surname><given-names>D.</given-names></name>
<name><surname>Hunger</surname><given-names>S.</given-names></name>
<name><surname>Carroll</surname><given-names>W.</given-names></name>
<name><surname>Devidas</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Germline genomic variants associated with childhood acute lymphoblastic leukemia</article-title>. <source>Nat Genet</source> <volume>41</volume>: <fpage>1001</fpage>–<lpage>1005</lpage>.</citation>
</ref>
<ref id="bibr162-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsai</surname><given-names>S.</given-names></name>
<name><surname>Martin</surname><given-names>D.</given-names></name>
<name><surname>Zon</surname><given-names>L.</given-names></name>
<name><surname>D’Andrea</surname><given-names>A.</given-names></name>
<name><surname>Wong</surname><given-names>G.</given-names></name>
<name><surname>Orkin</surname><given-names>S.</given-names></name>
</person-group> (<year>1989</year>) <article-title>Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells</article-title>. <source>Nature</source> <volume>339</volume>: <fpage>446</fpage>–<lpage>451</lpage>.</citation>
</ref>
<ref id="bibr163-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsai</surname><given-names>F.</given-names></name>
<name><surname>Orkin</surname><given-names>S.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation</article-title>. <source>Blood</source> <volume>89</volume>: <fpage>3636</fpage>–<lpage>3643</lpage>.</citation>
</ref>
<ref id="bibr164-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Väliaho</surname><given-names>J.</given-names></name>
<name><surname>Smith</surname><given-names>C.</given-names></name>
<name><surname>Vihinen</surname><given-names>M.</given-names></name>
</person-group> (<year>2006</year>) <article-title>BTKbase: the mutation database for X-linked agammaglobulinemia</article-title>. <source>Hum Mutat</source> <volume>27</volume>: <fpage>1209</fpage>–<lpage>1217</lpage>.</citation>
</ref>
<ref id="bibr165-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Varon</surname><given-names>R.</given-names></name>
<name><surname>Vissinga</surname><given-names>C.</given-names></name>
<name><surname>Platzer</surname><given-names>M.</given-names></name>
<name><surname>Cerosaletti</surname><given-names>K.</given-names></name>
<name><surname>Chrzanowska</surname><given-names>K.</given-names></name>
<name><surname>Saar</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome</article-title>. <source>Cell</source> <volume>93</volume>: <fpage>467</fpage>–<lpage>476</lpage>.</citation>
</ref>
<ref id="bibr166-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villa</surname><given-names>A.</given-names></name>
<name><surname>Notarangelo</surname><given-names>L.</given-names></name>
<name><surname>Macchi</surname><given-names>P.</given-names></name>
<name><surname>Mantuano</surname><given-names>E.</given-names></name>
<name><surname>Cavagni</surname><given-names>G.</given-names></name>
<name><surname>Brugnoni</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>1995</year>) <article-title>X–linked thrombocytopenia and Wiskott–Aldrich syndrome are allelic diseases with mutations in the WASP gene</article-title>. <source>Nat Genet</source> <volume>9</volume>: <fpage>414</fpage>–<lpage>417</lpage>.</citation>
</ref>
<ref id="bibr167-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vinh</surname><given-names>D.</given-names></name>
<name><surname>Patel</surname><given-names>S.</given-names></name>
<name><surname>Uzel</surname><given-names>G.</given-names></name>
<name><surname>Anderson</surname><given-names>V.</given-names></name>
<name><surname>Freeman</surname><given-names>A.</given-names></name>
<name><surname>Olivier</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia</article-title>. <source>Blood</source> <volume>115</volume>: <fpage>1519</fpage>–<lpage>1529</lpage>.</citation>
</ref>
<ref id="bibr168-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vlachos</surname><given-names>A.</given-names></name>
<name><surname>Ball</surname><given-names>S.</given-names></name>
<name><surname>Dahl</surname><given-names>N.</given-names></name>
<name><surname>Alter</surname><given-names>B.</given-names></name>
<name><surname>Sheth</surname><given-names>S.</given-names></name>
<name><surname>Ramenghi</surname><given-names>U.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference</article-title>. <source>Br J Haematol</source> <volume>142</volume>: <fpage>859</fpage>–<lpage>876</lpage>.</citation>
</ref>
<ref id="bibr169-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vlachos</surname><given-names>A.</given-names></name>
<name><surname>Rosenberg</surname><given-names>P.</given-names></name>
<name><surname>Atsidaftos</surname><given-names>E.</given-names></name>
<name><surname>Alter</surname><given-names>B.</given-names></name>
<name><surname>Lipton</surname><given-names>J.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry</article-title>. <source>Blood</source> <volume>119</volume>: <fpage>3815</fpage>–<lpage>3819</lpage>.</citation>
</ref>
<ref id="bibr170-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wagner</surname><given-names>J.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia</article-title>. <source>Blood</source> <volume>103</volume>: <fpage>3226</fpage>–<lpage>3229</lpage>.</citation>
</ref>
<ref id="bibr171-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wallace</surname><given-names>M.</given-names></name>
<name><surname>Marchuk</surname><given-names>D.</given-names></name>
<name><surname>Andersen</surname><given-names>L.</given-names></name>
<name><surname>Letcher</surname><given-names>R.</given-names></name>
<name><surname>Odeh</surname><given-names>H.</given-names></name>
<name><surname>Saulino</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>1990</year>) <article-title>Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients</article-title>. <source>Science</source> <volume>249</volume>: <fpage>181</fpage>–<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr172-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walne</surname><given-names>A.</given-names></name>
<name><surname>Dokal</surname><given-names>I.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Advances in the understanding of dyskeratosis congenita</article-title>. <source>Br J Haematol</source> <volume>145</volume>: <fpage>164</fpage>–<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr173-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Lasset</surname><given-names>C.</given-names></name>
<name><surname>Desseigne</surname><given-names>F.</given-names></name>
<name><surname>Frappaz</surname><given-names>D.</given-names></name>
<name><surname>Bergeron</surname><given-names>C.</given-names></name>
<name><surname>Navarro</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Neurofibromatosis and early onset of cancers in hMLH1-deficient children</article-title>. <source>Cancer Res</source> <volume>59</volume>: <fpage>294</fpage>–<lpage>297</lpage>.</citation>
</ref>
<ref id="bibr174-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Levy</surname><given-names>M.</given-names></name>
<name><surname>Lewis</surname><given-names>R.</given-names></name>
<name><surname>Chintagumpala</surname><given-names>M.</given-names></name>
<name><surname>Lev</surname><given-names>D.</given-names></name>
<name><surname>Rogers</surname><given-names>M.</given-names></name>
<name><surname>Plon</surname><given-names>S.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients</article-title>. <source>Am J Med Genet</source> <volume>102</volume>: <fpage>11</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr175-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wechsler</surname><given-names>J.</given-names></name>
<name><surname>Greene</surname><given-names>M.</given-names></name>
<name><surname>McDevitt</surname><given-names>M.</given-names></name>
<name><surname>Anastasi</surname><given-names>J.</given-names></name>
<name><surname>Karp</surname><given-names>J.</given-names></name>
<name><surname>Le Beau</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome</article-title>. <source>Nat Genet</source> <volume>32</volume>: <fpage>148</fpage>–<lpage>152</lpage>.</citation>
</ref>
<ref id="bibr176-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weemaes</surname><given-names>C.</given-names></name>
<name><surname>Hustinx</surname><given-names>T.</given-names></name>
<name><surname>Scheres</surname><given-names>J.</given-names></name>
<name><surname>van Munster</surname><given-names>P.</given-names></name>
<name><surname>Bakkeren</surname><given-names>J.</given-names></name>
<name><surname>Taalman</surname><given-names>R.</given-names></name>
</person-group> (<year>1981</year>) <article-title>A new chromosomal instability disorder: the Nijmegen breakage syndrome</article-title>. <source>Acta Paediatr Scand</source> <volume>70</volume>: <fpage>557</fpage>–<lpage>564</lpage>.</citation>
</ref>
<ref id="bibr177-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Whiteside</surname><given-names>D.</given-names></name>
<name><surname>McLeod</surname><given-names>R.</given-names></name>
<name><surname>Graham</surname><given-names>G.</given-names></name>
<name><surname>Steckley</surname><given-names>J.</given-names></name>
<name><surname>Booth</surname><given-names>K.</given-names></name>
<name><surname>Somerville</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple café-au-lait spots</article-title>. <source>Cancer Res</source> <volume>62</volume>: <fpage>359</fpage>–<lpage>362</lpage>.</citation>
</ref>
<ref id="bibr178-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Williams</surname><given-names>V.</given-names></name>
<name><surname>Lucas</surname><given-names>J.</given-names></name>
<name><surname>Babcock</surname><given-names>M.</given-names></name>
<name><surname>Gutmann</surname><given-names>D.</given-names></name>
<name><surname>Korf</surname><given-names>B.</given-names></name>
<name><surname>Maria</surname><given-names>B.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Neurofibromatosis type 1 revisited</article-title>. <source>Pediatrics</source> <volume>123</volume>: <fpage>124</fpage>–<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr179-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willig</surname><given-names>T.</given-names></name>
<name><surname>Gazda</surname><given-names>H.</given-names></name>
<name><surname>Sieff</surname><given-names>C.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Diamond–Blackfan anemia</article-title>. <source>Curr Opin Hematol</source> <volume>7</volume>: <fpage>85</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr180-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wimmer</surname><given-names>K.</given-names></name>
<name><surname>Etzler</surname><given-names>J.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?</article-title> <source>Hum Genet</source> <volume>124</volume>: <fpage>105</fpage>–<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr181-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winkelstein</surname><given-names>J.</given-names></name>
<name><surname>Marino</surname><given-names>M.</given-names></name>
<name><surname>Lederman</surname><given-names>H.</given-names></name>
<name><surname>Jones</surname><given-names>S.</given-names></name>
<name><surname>Sullivan</surname><given-names>K.</given-names></name>
<name><surname>Burks</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>X-linked agammaglobulinemia</article-title>. <source>Medicine</source> <volume>85</volume>: <fpage>193</fpage>–<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr182-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xu</surname><given-names>G.</given-names></name>
<name><surname>O’Connell</surname><given-names>P.</given-names></name>
<name><surname>Viskochil</surname><given-names>D.</given-names></name>
<name><surname>Cawthon</surname><given-names>R.</given-names></name>
<name><surname>Robertson</surname><given-names>M.</given-names></name>
<name><surname>Culver</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>1990</year>) <article-title>The neurofibromatosis type 1 gene encodes a protein related to GAP</article-title>. <source>Cell</source> <volume>62</volume>: <fpage>599</fpage>–<lpage>608</lpage>.</citation>
</ref>
<ref id="bibr183-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia</article-title>. <source>JAMA</source> <volume>301</volume>: <fpage>393</fpage>–<lpage>403</lpage>.</citation>
</ref>
<ref id="bibr184-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Cheng</surname><given-names>C.</given-names></name>
<name><surname>Devidas</surname><given-names>M.</given-names></name>
<name><surname>Cao</surname><given-names>X.</given-names></name>
<name><surname>Campana</surname><given-names>D.</given-names></name>
<name><surname>Yang</surname><given-names>W.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia</article-title>. <source>Blood</source> <volume>120</volume>: <fpage>4197</fpage>–<lpage>4204</lpage>.</citation>
</ref>
<ref id="bibr185-2040620713498161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zaza</surname><given-names>G.</given-names></name>
<name><surname>Cheok</surname><given-names>M.</given-names></name>
<name><surname>Yang</surname><given-names>W.</given-names></name>
<name><surname>Panetta</surname><given-names>J.</given-names></name>
<name><surname>Pui</surname><given-names>C.</given-names></name>
<name><surname>Relling</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment</article-title>. <source>Blood</source> <volume>106</volume>: <fpage>1778</fpage>–<lpage>1785</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>